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25.108 Kidney transplants in human recipients have been registered through-
out the world up to 1977 (118). Serological histocompatibility matching 
in related donor recipient combinations has a definite effect on the outcome 
of the renal graft (1 08, 119, 131 ). However, the relevance of histocomp-
atibility matching in cadaver kidney transplants is less clear. Matching for 
human leukocyte antigens (HLA) can be performed by serological techni-
ques. Lymphocytes of the donor and the prospective recipient are tested 
against a panel of specific antisera. Leukocyte antigens are recognized. The 
patterns formed by means of the antisera are controlled by loci of the major 
histocompatibility complex (MHC). HLA-A and HLA-B are serological-
ly defined (SD) loci. Several international kidney exchange organisations 
perform prospective matching for HLA in order to improve outcome of renal 
cadaveric transplant survival. Identity for HLA has a beneficial effect on 
renal allografts according to many studies (5, 12a, 24, 38, 83, 98, 107, 109, 
120, 123), although these finding are not confirmed by others (82, 112). 
Van Hooff eta!. (54), Oliver eta!. (92, 93) and van Rood eta! (121) report 
that matching for HLA is particularly important in the presence of pre-formed 
antibodies and identity for HLA-B antigens is of greater importance 
than identity for HLA-A antigens. Recently Opelz et a!. have reported the 
correlation between HLA matching and graft survival in different transplan-
tation centers (I 04, 1 07). The relevance of histocompatibility matching was 
greatly affected by the quality of the transplantation center. Centers with an 
excellent one year transplant survival showed only some correlation between 
histocompatibility matching and transplant survival, whereas such correlat-
ion was highly significant in centers with a poor one year graft survival. 
Matching for the serologically defined loci of the major histocompati-
bility complex (MHC) HLA-A and HLA-B has not improved one year kidney 
graft survival and this figure is still depressingly low (about 50%) (117, 118). 
Experimental and clinical observations stress the importance of matching 
for determinants of HLA-D, being another locus of the MHC, that can 
be recognized by mixed lymphocyte reaction (MLR) tests. (22, 55, 106). 
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Lymphocytes of the kidney donor and prospective recipient can be cultured 
in a medium (mixed lymphocyte culture). Lymphocytes of subjects non-
identical for the lymphocyte defined (LD) HLA-D will be stimulated to 
grow, whereas cells of HLA-D identical subjects do not grow in mixed lym-
phocyte cultures. Since these tests take at least 5 days, they are too time 
consuming to be used for prospective matching in cadaver kidney transplan-
tations. Serological techniques for matching for HLA-D will probably be 
available in the near future (122). 
The presence of preformed lymphocytotoxic antibodies in the serum of 
the prospective kidney recipient leads to hyperacute graft rejection, when 
these antibodies are directed against the kidney donor (71, II 0). Antibodies 
that are not directed against the kidney donor, when the crossmatch test 
between recipient's serum and donor's cells is negative, can also influence 
graft survival by causing accelerated rejection, according to many publica-
tions (7, 54, 84, 91, 92, 93, 9 5, 97, I 07, Ill, 117, 118, 121, 13 7). Observ-
ations of others do however not support these data (8, 9, 17, 36, 72). The 
fear for stimulation of antibody production kept nephrologists and trans-
plantation physicians from treating their prospective kidney donors with 
blood transfusions. 
Yet a deterioration of the renal transplant results was observed as report-
ed by Terasaki et a!., (138) and byvan Hooff eta!. (56), for which the 
change in blood transfusion policy was thought to be, at least partly, re-
sponsible. 
Accelerated renal allograft rejection after multiple blood transfusions 
was not observed and even a paradoxical effect of blood transfusion was re-
ported in early studies of human kidney grafts (27, 60, 81, 85). In 1973 a 
protective effect of pretransplant blood transfusions on the outcome of 
cadaver kidney transplants was reported by Opelz et a!. in a retrospective 
study (97). These data heve been confirmed by his and other groups in 
retro- and prospective studies (3, 12a, 39, 42, 42a, 87, 99, 102, !05). The 
one year graft survival of non-transfused kidney graft recipients was very 
low (12a, 56). Still blood transfusions may lead to antibody production 
against a percentage of a leukocyte panel in many cases and fear for accele-
rated graft rejection still leads to the restriction of the number of blood 
transfusions given to future recipients and more often future recipients have 
not been transfused at all. And as long as there is still some skepticism 
about a general transfusion policy ( 4 ), in vivo and in vitro experiments will 
be necessary to elucidate the effect of blood transfusions on renal allograft 
survival in man. 
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Transplantation experiments in well controlled animal models have to 
be carried out to study the effect of blood transfusions on allograft survival 
and antibody production in order to design an optimal transfusion policy. 
Because of the experience in our laboratory with transplantation studies in 
DLA tissue typed beagles this model was also chosen for the present expe-
riments. The aim of our investigation was therefore to study renal allograft 
survival after different blood pretreatment schemes in DLA tissue typed 
beagles. 
In this thesis the results of kidney transplantation experiments, that have 
been performed in the Surgical Laboratory of the Erasmus University, Rot-
terdam, the Netherlands are reported. 
Chapter 2 contains a survey of the literature on the effect of blood trans-
fusions on kidney transplant survival in man. The relevance of histocompati-
bility matching and presensitization is also considered in this chapter. 
In Chapter 3 experimental data on kidney transplantation after pretreat-
ment with blood or other antigens in small rodents, dogs and rhesus mon-
keys, as presented in the literature, are summarized. Data on active enhance-
ment will get special attention in the light of our experimental work. 
In Chapter 4 experiments testing the effect of one i.v. transfusion of do-
nor blood on renal allograft survival in DLA identical, one and two DLA 
haplotype different littermates are reported. 
Chapter 5 contains the report of experiments in which graft protection by 
s.c. donor blood injections prior to transplantation has been tested in beagle 
litterrnates. (2 DLA haplotype different). 
In Chapter 6 experimental data on renal allotransplant survival have been 
reported after multiple transfusions in the recipient with pooled blood from 
non related blood donors. The segregation of immune responsiveness has 
been studied in this model. DLA identical and non-identicallittermates 
have been used. 
Chapter 7 contains a report of the effect of blood transfusions from related 
blood donors (father or mother of kidney donor and recipient) on the survi-
val of renal allografts of DLA identicallittermates. Parental blood was used 
in order to prevent a positive crossmatch and to obtain enhancing antibodies 
against non D LA antigens. 
Chapter 8 contains the experimental data on the effect of third party non 
related blood transfusions on renal allograft survival in immunosuppres-
sed beagles. 
Chapter 9 contains a general discussion about the findings presented in 
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the foregoing chapters and a summary in English and Dutch language conclud-
es this thesis. 
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CHAPTER 2 
Effect of blood transfusions on renal allograft survival in man 
2.1. Introduction 
Lymphocytotoxic antibodies, that can be detected in prospective kidney 
recipients will be a result of pregnancies, blood transfusions or former alia-
transplantations. Females which did not receive blood transfusions in the 
past have antibodies in 19% of the cases, whereas males have antibodies in 
only 4% of the cases (96). The difference is obviously the result of pregnanc-
ies and in males the positive cytotoxic antibodies must be a result of cross-
reaction with other antigens or due to an errvr in technique. Prior to trans-
plantation (after hemodialysis and transfusions) 30.4% of all female pro-
spective kidney graft recipients are presensitized and 19.5% of all male pro-
spective recipients have cytotoxic antibodies (I 03 ). 
Although a clear correlation exists between duration of hemodialysis and 
the number of blood transfusions (73 ), only 20-25% of prospective recipients 
have cytotoxins regardless of the duration of hemodialysis as has been report-
ed by Terasaki eta!. (137). This percentage is relatively low because of loss 
of antibodies (94 ). Antibody levels can decrease after some time result-
ing in a so-called secondary unresponsiveness (37); also about one half 
of the patients do not produce antibodies at all during a period of one 
year of hemodialysis according to Opelz et al.(94). It is clear that the leuko-
cytes in the transfused blood play a role in the degree of sensitization. Frozen 
blood which is depleted ofleukocytes (42) and leukocyte poor blood give 
(21) less sensitization. Casely et a!. (21) have detected antibodies in 76% of 
the patients that received whole blood during dialysis, whereas patients that 
have been treated with leukocyte poor blood did not produce cytotoxins at 
all (21 ). Frozen blood gives antibody production in 4.8% of the cases versus 
whole blood in 20%, as reported by Fuller eta!. (42). To prevent the pro-
duction of lymphocytotoxic antibodies, leukocyte poor or frozen blood will 
probably be the ideal treatment for patients awaiting a renal graft. Opelz et 
aL (99) report however that the beneficial effect on renal grafts, as can be in-
duced by whole blood transfusions is not seen when frozen blood has been 
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used instead. Fuller eta!. (42, 42a) and Briggs eta!. (12a), on the other hand, 
observe an equal degree of graft protection by either whole or frozen blood. 
No supportive data can be found for a policy as advised by Lucas et a!. 
(76) of transplanting hemodialysis patients as early as possible regardless of the 
tissue match, in order to avoid sensitization by blood transfusions. On the 
other hand, blood transfusions are not altogether harmless. Although 
non-transfused kidney graft recipients have a greater graft failure rate, sen-
sitization by blood transfusions will increase with the length of hemodialy-
sis. Thus, the chance of antibodies against a high percentage of prospective 
kidney donors will increase. Patients will be lost for transplantation by a 
liberal blood transfusion policy (4, 42a). 
2.2. Sensitization and renal allograft survival 
Presence of lymphocytotoxins in the prospective recipient directed against 
the kidney donor transplantation antigens as estimated by a strong positive 
crossmatch test will give rise to hyperacute rejection of the allograft (71, 
11 0). A weak positive crossmatch reaction can be caused by the presence 
of antibodies directed against non HLA antigens present on B lymphocytes 
which themselves may have an enhancing effect (32). These antibodies may have 
an analogy to antibodies directed towards immune response locus associated 
antigens (Ia) in mice. 
Graft prognosis may be worse in the presence of cytotoxic antibodies, 
which are not directed against the kidney donor but instead are cytotoxic 
against a percentage of a panel of leukocyte donors, as has been reported in 
several publications (7, 54, 84, 91, 92, 93, 95, 97, 107, 111, 117, 118, 121, 
137). Prospective recipients who did not produce lymphocytotoxic antibodies 
after more than one year duration of hemodialysis had a one year graft 
survival of 85%, whereas recipients who did not produce antibodies in less 
than one year of hemodialysis had a one year graft survival of 50% (94, 
95). 
The observation that the presence of cytotoxic antibodies influences 
graft prognosis has not been confirmed by other groups (8, 9, 12a, 17, 36, 
73 ). Callender et a!. (17) report the follow-up of 185 renal allograft re-
cipients from a transplantation center, well-known for its good results (129, 
130). Thirty-two patients who showed anti HLA antibodies against more 
than 15% of a panel were compared with the same number of patients, who 
did not have antibodies. The patients were matched as to sex, age of recipient, 
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time of transplantation and other factors. No difference between the two 
groups (positive antibodies: 78% one year graft survival, negative antibodies: 
74% one year survival) was observed. In their communication there is no evi-
dence that "responders" and "nonresponders" behave differently, as has 
been suggested by Opelz eta!. (94). Ferguson et al. (36), report that divi-
sion into responders and non-responders on the basis of the presence of 
lymphocytotoxic antibodies has little relation with the ultimate graft func-
tion. A sensitive crossmatch technique prevents the transplantation of a 
graft that can be rejected in an accelerated way. Graft prognosis will be 
the same regardless of whether antibodies are present as long as a sensitive 
crossmatching technique is used. 
2.2.1. Sensitization and survival of related and non-related renal allografts 
In the 13th report of the Human Renal Transplant Registry (1977) (118) a 
significantly shorter graft survival in presensitized recipients of cadaver grafts 
over non sensitized recipients has been reported. In recipients of a graft of 
a living related donor such difference has no statistical significance. 
2.2.2. Relation between sensitization and sex 
Beleil et a!. (7) have reported that no difference in renal transplant survival 
could be found between female and male recipients, although preformed cy-
totoxins were twice as frequent among females. Graft survival of female re-
cipients was not influenced by the presence of preformed antibodies. The 
graft survival time in male recipients with antibodies was shorter than in 
those without. Opelz et al. (I 03) report in their series that female recipients 
received an unexpectedly high number of blood transfusion prior to trans-
plantation as compared to males. 
2.2.3. Sensitization, histocompatibility matching and renal allograft sur-
vival 
Matching for HLA antigens has a very great influence on survival of related 
donor kidneys (108, 119, 131). The effect ofHLAmatching on cadaver donor 
transplants has been studied by many authors. In the earliest reports on 
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this subject Patel eta!. in 1968 (109), Morris eta!. in 1968 (83), van Rood et 
a!. in 1969 (120) and Batchelor eta!. in 1969 (5) have observed a positive 
influence of matching for HLA on renal cadaveric graft survival. However, 
only small groups of patients were included in these investigations and a 
limited number of HLA antigens was known by that time. In confirmation 
with these early findings were the observations made by Festenstein eta!. 
(38), Hors eta!. (58) and Perkins eta!. (114). In 1971 the correlation be-
tween HLA matching and renal cadaveric graft survival was critized by Mickey 
eta!. (82) who did not find such a correlation in 487 patients in North Amer-
ica. But since that time the reports of van Hooff et a!. (54) and Oliver et al (92, 
93) in 1972 and of van Rood et al. (121) in 1973 and especially the very clear 
data of the combined France and London transplant groups presented by 
Dausset et al. (24) in 1974, and later of Sachs et a!. (123), made the 
relevance of matching for HLA antigens very likely for cadaver renal trans-
plants. Dausset eta!. (24) reported a 2 year cadaver graft survival in recipients 
that had 4 HLA antigens in common with the kidney donor of 70% ± 7%. 
When 3 HLA antigens were common: 54%± 7%, when 2 HLA antigens were 
common: 45% ± 3%, and when 1 or zero HLA antigen was common: 34% ± 
4% 2 year graft survival was found respectively. Oliver et a!. (92, 93 ), van 
Hooff et a!. (54) and van Rood et a!. (121) showed HLA matching only to 
be useful in the presence of cytotoxic antibodies whereas matching for 
HLA-B was more relevant than matching for HLA-A. 
The North-American kidney graft survival data were examined by Opelz 
et a!. (98) in 1974. Only a marginal influence of HLA-matching in 2172 
cadaver graft recipients from eighty transplantation centers was found. In are-
cent survey by the same group (1 07) in 1977 a highly significant correlation 
between matching for HLA and renal graft survival in 4,851 cadaver donor 
grafts was reported. HLA-A locus derived antigens expressed a slightly 
stronger effect than did HLA-B locus derived antigens. The influence of HLA 
matching is most significant in transplantation centers having the poorest one 
year transplant survival(< 40%). However, in the presence of cytotoxic anti-
bodies matching for HLA did not give a better correlation as could be ex-
pected from studies by others (54, 92, 93, 121). In another communication 
from Opelz et al. (1 03) in 1977 HLA matching was only shown to be of value 
in male recipients regardless of the presence of cytotoxic antibodies. 
Although matching for HLA-A and HLA-B will probably improve the out-
come of renal cadaver grafts, one year graft survival is still around 50% (118). 
This is the case probably because other loci of the major histocompatibility 
complex (MHC) and minor histocompatibility differences affect graft sur-
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viva!. The locus that is represented by the reaction in the mixed lymphocyte 
culture is called HLA-D. Identity for the HLA-D derived antigens between 
kidney transplant donor and recipient has a positive effect on renal graft 
survival. Matching for HLA-D by mixed lymphocyte reactions (MLR) will 
prolong cadaver kidney graft survival in human recipients already matched 
for serologically defined antigens (22,55,106). In dogs, such an improve-
ment of allograft outcome could not be observed due to the high linkage 
disequilibrium between DLA-A, DLA-B and DLA-D (16). 
In a recent communication (I 06) a good correlation was found for match-
ing for HLA-D and kidney allograft prognosis in 131 human cadaver kid-
ney recipients. The mixed lymphocyte culture is too time consuming to be 
used for prospective selection of cadaver graft recipients. Recognition of 
HLA-D determinants may be possible in the future by serological means 
since a linkage disequilibrium exsists between HLA-B and HLA-D (55) and 
detection of HLA-D antigens by means of B-cell sera will probably be feas-
ible as well (122). 
2.2.3. Blood transfusions and renal allograft survival 
Blood transfusions are equated with immunization and accelerated graft re-
jection and no blood transfusions or leukocyte poor blood have been recom-
manded, although a paradoxical effect of pre-transplant blood trans-
fusions was observed as early as 1966 (81). Instead of expected in-
crease in numbers of rejection episodes or accelerated rejection after an in-
creasing number of blood transfusions, a normal rejection reaction (or in 
some cases a so-called paradoxical effect) has been observed in human kid-
ney graft recipients (27, 60, 81, 85). However, the number of recipients was 
small in those studies and the differences were not highly significant. In a 
retrospective survey of 148 kidney recipients in 1973 (97) Opelz et a!. re-
ported the striking effect of blood transfusions prior to transplantation on 
graft prognosis. After more than I 0 blood transfusions the one year graft 
survival was 66% ± 7% for the group as a whole and 80% ± 8% for transfused 
recipients without lymphocytotoxins. The one year graft survival of non-trans-
fused recipients was a mere 29% ± 6% in the same series. The deterioration 
of overall kidney transplant results, as has been reported by Terasaki et al. 
( 13 8), was though to be a result of the changed blood transfusion policy 
for prospective kidney transplants. Since 1969 the number of blood trans-
fusions was reduced in patients on hemodialysis in order to prevent antibody 
production. 
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The data of Opelz et al. (97) in 1973 stressing the benificial effect of 
blood transfusions on the outcome of renal grafts have more recently been 
confirmed in many studies (3, 12a, 39, 42, 42a, 56, 87, 99, 102, 105lc.Van 
Hooff et al. (56) reported a significant decrease in kidney graft survival when 
the number of blood transfusion given prior to transplantation was dropped. 
Until 1972 prospective recipients received a median number of blood 
transfusions of 20 to 30. Since 1972 this number has decreased to only 
three. In this study (56) an increased one year cadaver kidney graft survival was 
seen in recipients that received blood transfusions prior to transplantation. 
(see table below) 
0 transfusion 17% 1 year surv. (18 pts) 
1- 4 transfusions 67% 1 year surv. (33 pts) 
11-20 transfusions 74% 1 year surv. (35 pts) 
21-40 transfusions 89% 1 year surv. (30 pts) 
> 40 transfusions 69% 1 year surv. (29 pts) 
unknown number 83% 1 year surv. ( 6 pts) 
from van Hooff, thesis (57). 
Recipeints, which had received transfusions of frozen blood have been stu-
died by Opelz et al. (99). Between them and the recipients which did not re-
ceive any blood transfusions at all no difference in outcome of kidney 
transplant was observed (28% ± 6%), whereas those recipients which were 
transfused with whole blood prior to transplantation had an one year graft 
survival of 51%± 1%. 
In recent publications by Fuller et al. (42, 42a) tht one year graft survi-
val of patients, transfused with frozen blood was as good as the graft survi-
val of patieints who were transfused with whole blood. The stimulation for 
antibody production was very low after frozen blood transfusions. However, 
the deglycerolization procedure of the frozen blood before transfusion was 
important for the protective effect on renal allografts. Deglycerolization by 
agglomeration (DGA) resulted in a lower percentage of HLA lymphocyto-
toxins and a better 2 year graft survival, whereas deglycerolization by centri-
fugal washing (DGC) resulted in a higher percentage of antibodies and a lo-
wer graft survival (42, 42a) (see table). The presence of HLA antibodies also 
precluded or delayed renal allografting in transplant candidates. Fuller et 
a!. ( 42a) report that following a dialysis period of nearly 8 months 44% of 
the sensitized patients underwent transplantation, whereas more than 90% 
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of the non-sensitized patients received an allograft within two months of 
their acceptance in the program. 
patients antibodies 2 year graft survival 
non-transfused 10 0% 25,0% 
whole blood + frozen 
blood 80 20% 47,1% 
frozen blood only 39 13,2% 47,6% 
frozen blood (DGA) 21 4,8% 55,4% 
frozen blood (DGC) 12 16,6% 31,8% 
from: Fuller et al. Transpl. Proc. 9, 117, 1977 (42). 
Also Briggs eta!. ( 12a) reported an improvement of one year graft survi-
val after transfusions of whole blood as well as of frozen-thawed blood. 
These data are very promising, especially since transfusions with frozen 
blood have also the advantage of not transferring hepatitis (59). In a recent 
communication about the results of 382 recipients of cadaver kidneys (102) 
in which the transfusion data had been collected prospectively, patients 
which did not receive blood transfusions had a inferior graft survival after I 
year (31%± 4%)and after two years (21%± 4%). 10 out of these non-trans-
fused patients had preformed antibodies. 9 out of these 10 grafts failed 
within the first year. Recipients who had received 1-5 blood transfusions 
had a better one year graft survival: 57% for recipients with preformed anti-
bodies and 54% for recipients without antibodies. Thus, the presence of 
antibodies did not effect graft survival in this group, but did influence the 
one year graft survival (37%) of those recipients who received more than 5 
blood transfusions prior to grafting, whereas in the absence of antibodies the 
one year graft survival was 51%. Thus no further improvement by an increas-
ing number of bloof transfusions could be seen. It will be evident that the 
graft survival data, as presented by van Hooff in the Netherlands (56) show 
a qualitative difference with those presented by Opelz in the U.S. (107). 
Many other factors must have an effect on renal graft survival. And 
difference in quality between various centers is such that well matched kid-
neys in poor centers (I year graft survival < 40%) have a worse prognosis 
than badly matched kidneys in a good transplantation center (I year graft 
survival> 40%) (l 04, I 07). 
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2.4 Conclusion 
The outcome of renal cadaver transplants is greatly influenced by matching 
for HLA antigens. One year graft survival is however still low (about 50%). 
Matching for the HLA-D locus by MLC or serological techniques will pro-
bably improve transplantation results in the near future. Since transplant 
survival shows a wide variation in different transplantation centers improve-
ment in patient care in those centers with poor results will probably im-
prove the overall transplantation results. 
In the last few years a consistent decrease of graft survival has been ob-
served, partly due to a diminished number of blood transfusions to the pro-
spective graft recipients. In the past the policy of restricting blood transfu-
sions has been advised in order to prevent the formation of lymphocyto-
toxic antibodies with the chance of accelerated graft rejection. Recently it be-
came clear that preformed antibodies do not have a deleterious effect as 
long as crossmatch tests are being performed in an accurate way. 
A beneficial effect on kidney transplants of pretransplant transfusions 
with whole blood has been reported by several groups. This effect is more 
pronounced when no antibodies have been formed, according to most re-
ports. Increase of the number of blood transfusions does not further im-
prove the benificial influence on renal allograft survival in man. Frozen 
blood may be used with an equal beneficial effect as has been shown by 
the promising data of two groups. 
Although the protective effect of blood transfusions seems evident, par-
ticulary on poorly matched cadaver renal grafts, the risk of sensitization 
will always be present and some patients will be lost for transplantation by 
an universal transfusion policy. Further in vivo and in vitro experiments 
need to be carried out to study whether an improved outcome of the kid-
ney transplants will compensate for the loss of potential kidney recipients. 
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CHAPTER 3 
Effect of blood transfusions on renal allograft survival in experimental ani-
mals 
Pretreatment with blood of the prospective kidney donor or of a third party 
blood donor with or without the addition of immunosuppressive treatment 
has been shown to have a beneficial effect on kidney grafts in rats (34, 35, 
77) and in rare cases in rabbits (29), dogs (I, 48) and rhesus-monkeys (31 ). 
Prolonged graft survival by preventing or delaying the allograft rejection 
after pretreatment with donor antigen has a long history. Flexner and 
Jobling (1907) (40) observed a prolonged survival of transplantable sarcoma 
in rats after pretreatment of these rats with the same tumor. Since that time 
much work has been carried out on immunological enhancement, as this phe-
nomenon was called. 
3.1. Immunological enhancement 
Enhancement is an antibody dependent phenomenon, resulting in prolonged 
survival of an allogeneic graft (69). Immunological enhancement can become 
so pronounced, that indefinite prolongation of graft survival can be achieved 
without the use of immunosuppressive treatment. Many reviews on enhance-
ment and many communications dealing with the possible mechanisms of 
enhancement have been published. (2, 6, 41, 69, 70, 74, 133, 136). 
Immunological enhancement can be achieved by active conditioning of 
the recipient with the antigens of the prospective donor or donor strain 
(34, 35, 66, 77, 78, 88) or passive immunization with appropriate antibody 
raised by hyperimmunization of a recipient strain (i.e. antidonor serum) (33, 
135). Also a combination of antibody and antigen can be used (70, 90, 135). 
Enhancement can be considered as the opposite to rejection. Enhancement 
as well as rejection of a graft is induced by antibodies against the antigens 
that determine histocompatibility between donor and recipient. The relevant 
antibodies in immunological enhancement are directed against alloantigens 
determined by the MHC by which donor and recipient differ. These anti-
bodies can be identified by lymphocytotoxicity or haemagglutinating tests 
23 
in some species and possibly by a weak crossmatch test or positive B-lympho-
cyte crossmatch test in humans (32), or by blocking factor activity in mixed 
lymphocyte cultures. (116, 126, 127, 128). Further studies have been car-
ried out to identify which antigens are concerned with the production of 
enhancing antibodies. In mice, antigens determined by the Immune region 
of the MHC (Ir) or Immune region associated antigens (Ia) are thought to 
be responsible for induction of enhancement (25, 61 ). 
In the light of our studies on the effect of blood transfusions on renal allo-
graft survival in DLA-tissue typed beagle littermates, we will focus in 
the next paragraph on the reports about experiments in rodents, which 
deal with active enhancement of renal allografts, particularly when 
whole blood has been used as antigen. Reports of succesful renal allograft 
protection by (donor) blood in larger experimental animals are rare. We 
shall therefore analyse in the following paragraph all transplantation experi-
ments in dogs in which prolongation of kidney graft survival by immuno-
logical manupulations had been the main object of investigation. 
3.2. Active immunological enhancement of allografts by donor blood in 
rodents 
Active immunological enhancement of allografts by pretreatment with whole 
blood has been reported by several authors (34, 35, 66, 77, 78). Marquet et 
al. (77) have reported the effect of donor strain blood on renal and heart 
allograft survival in two rat models. In the BN to Wag/Rij model indefinite 
survival of heart allografts and prolonged survival of renal allografts could 
be achieved by one injection of donor strain blood one week prior to trans-
plantation, whereas in the reversed model (Wag/Rij to BN rats) accelerated 
rejection was seen after the same pretreatment schedule. When immuno-
suppressive therapy had been given at the time of blood injection in-
definite survival of heart allografts and prolonged survival of renal allografts 
was seen. Indefinite survival was also achieved in this model when com-
plexes of donor antigen and anti-donor strain antibody were added to donor 
blood pretreatment as reported by Marquet et al. in a recent publica-
tion (80). 
Immunosuppression that could prevent graft rejection in one model 
could also prevent immunological enhancement in another model (78). 
The antagonistic effect of immunosuppressive drugs on immunological 
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enhancement has also been reported by My burgh et a!. for liver allografts 
in baboons (88). 
Fabre and Morris (34) were led to their studies in rats at that time by 
the observations ofHume, Michielsen, Dossetor and Morris (27, 60, 81, 85) 
describing a possible benificial effect of blood transfusions in human renal 
allograft recipients. Specific immunosuppression (enhancement or tolerance) 
of renal allografts by one i.v. injection of donor strain blood I week 
prior to grafting could easily been achieved in a "weak" rat model. The 
(DA x Lewis) FJ to Lewis rat model represented the strongest incompatibil-
ity, characterized by a vigorous unmodified rejection and ready production 
of lymphocytotoxins. In this "strong" rat model immunological enhance-
ment could only be achieved by multiple pretransplant blood injections. 
Further studies by the same group (35) showed that donor serum could 
not elicit enhancement. It was concluded that the effect was due to the 
cellular elements of the blood. Passive transfer of serum of long surviving 
rats did not lead to enhancement, whereas passive enhancement by treat-
ment with hyperimmune anti-donor serum is very well possible in the same 
experimental model (33). 
From these and other investigations it is clear that a delicate balance 
exists between accelerated rejection and prolonged allograft survival after 
donor antigen (blood) pretreatment in rats due to t)le presence of en-
hancing and/or cytotoxic antibodies. 
Prolongation of graft survival depends on histocompatibility between 
donor and recipient, dosage of antigen, timing of antigen injection and 
transplantation, route of injection and additional aspecific immunosuppres-
sive treatment (78, 90). 
3.3. Enhancement of renal allografts in the dog 
In contrast with the easily obtainable prolongation of renal allograft sur-
vival by blood pretreatment in rodents, pretreatment with blood transfusions 
rarely leads to protection of renal allografts in dogs. In larger out bred expe-
rimental animals like dogs, reports of prolongation of allograft survival by 
pretransplant immunological manipulation are scarce and seldom well 
documented. In the light of our own experiments in DLA tissue typed dogs, 
which are presented in this thesis, reports of experiments in dogs concern-
ing renal allograft survival after blood pretreatment will be reviewed more 
in detail. 
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Prolongation of renal allograft survival in non tissue typed mongrel dogs 
was achieved in 1964, by Halasz eta!. (48). Two mi. of whole donor 
blood was injected subcutaneously in the prospective kidney recipient 
10 and 5 days prior to renal grafting. This form of pretreatment resulted 
in a significantly better outcome of the graft when compared with renal al-
lograft survival in non-pretreated mongrels. No antibodies were estimated 
prior to transplantation. These results are impressive, although a certain dis-
crepancy in histocompatibility between donor and recipient combinations 
in the experimental and the control group cannot be excluded. Many authors 
have referred to this communication as an example of active enhance-
ment in the dog. It is even more interesting that by the foregoing pretreat-
ment scheme skin allografts could be protected as well ( 4 7), although skin 
grafts are supposed to be more immunogeneic than vascularized grafts. 
Halasz eta!. (49) also studied the effect ofi.v. donor spleen cells on allo-
graft survival in mongrel dogs. In their opinion large amounts of donor anti-
gens were necessary to prolong renal graft survival. This observation seems 
in contrast with the low dosage used in earlier experiments (48). Pretreat-
ment with high doses of spleen cells did not lead to prolongation of kidhey 
graft survival, but when low doses of immunosuppressive drugs were added 
or when an antigen extract was used, prolongation of graft survival was 
achieved. 
Linnet a!. (75) reported in 1966 an experiment in which mongrel dogs 
were pretreated with spleen cells of the prospective donor two weeks prior to 
transplantation or post-transplantation. Renal allografting was performed 
by implanting the kidney in the recipient's neck. No nephrectomy was 
performed and no immunosuppressive therapy was given. The renal allo-
graft survival was prolonged in the dogs that had received pretransplant 
antigen treatment compared with non-treated dogs and dogs that received 
the spleen cell solution after transplantation. The difference was however 
barely significant. 
Caine et a!. (18) used several different pretreatment schemes in canine 
renal allograft experiments. Mongrel dogs were used and third party blood 
transfusions, donor spleen cells, donor lymphe node cells, donor bone 
marrow and a semi-soluble antigen derived from donor spleen cells were 
used as pretreatment antigens. No influence on renal allograft survival in 
non related mongrel dogs could be observed, whether immunosuppressive 
drugs were given or not. 
Caine eta!. (18) suggested that the genetic differences between outbred 
dogs were too great to be overcome by the amount of antigeneic matter 
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available from one single donor. Another possibility could be that the right 
scheme had not been found or that immunological reactivity of dogs could 
not be compared with that of small rodents. 
Zimmerman eta!. (149) pretreated mongrel dogs by repeated i.v. injec-
tions of subcellular fragments of spleen cells, used as donor antigens over a 
two week period, without immunosuppression. A small but statistically in-
significant renal graft prolongation had been observed. But when antigen 
dosage was increased or when the course of injections was continued longer 
than three weeks, effectiveness was lost or accelerated rejection was found. 
When small doses of immunosuppressive drugs were given postoperatively 
in this protocol a dramatically prolonged survival time of renal allografts 
was observed in this model by Wilson et al. (147, 148). When the solubiliz-
ed antigen had been derived from donor lymphocytes still a considerable 
prolongation of renal graft survival was achieved in mongrel dogs (52, 53). 
The doses of immunosuppressive drugs alone did not lead to prolongation 
of graft survival. Patterns of antibody production were related to 
duration of pretreatment and dosage of antigen and only cytotoxic anti-
bodies were measured. 
Currier and Pierce (23) reported the effect of donor blood transfusions on 
antibody production and renal allograft survival in mongrel dogs. Transfus-
ions were given three and two weeks prior to grafting and low immunosup-
pressive treatment postoperatively. Cytotoxic antibodies were measured imme-
diately before transplantation. After transfusion with whole blood 5 out of I 0 
recipients produced antibodies and 4 out of I 0 recipients showed accelerated 
rejection. The longest survival was 16 days. When, however, leukocyte poor 
blood had been transfused no lymphocytotoxic antibodies could be detect-
ed and the longest graft survival was ten months. 
J eekel et a!. ( 63) carried out experiments in D LA tissue typed beagle litter-
mates in our laboratory in order to achieve active and passive enhancement 
of renal allografts. For each set of experiments two DLA identical litter-
mates were selected. One recipient had been immunized by weekly s.c. 
injections of peripheral lymphocytes of the prospective kidney donor to 
raise anti-donor serum. The other recipient was treated with the anti-donor 
serum. The immunization scheme had been adapted from immunization 
schemes used in enhancement experiments in mice and rats (62, 64). Kid-
neys of a I haplotype different littermate donor were grafted in the two re-
cipients. The kidneys in the hyperimmunized recipients were rejected in an 
accelerated way. Out of the 6 dogs that had been treated with antidonor serum 
2 had a prolonged survival of 70 and 250 days without histological 
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signs of rejection, whereas control DLA 1 haplotype different kidney trans-
plants had a mean survival of 18,5 days (10 to 44 days) (145). Passive en-
hancement of renal allograft was thus achieved, although these results could 
not be reproduced in later experiments. 
In the same dog model i.v. injection of bone marrow cells of the prospective 
kidney donor did not increase the prolongation of renal allograft survival which 
had already been obtained by a short course of horse anti dog lymphocyte serum 
(65). Thus combination of ALS and donor bone marrow cells did not produce 
enhancement of renal allografts as described by the group of Monaco (20). 
Storb eta!. (134) studied the effect of blood transfusions on bone marrow 
grafting between histocompatible canine siblings. 100 ml donor blood 
given ten days prior to whole body radiation gave accelerated rejection of 
DLA identical bone marrow grafts when compared with engraftment in non-
transfused dogs. 
In a recent communication Abouna et a!. (1) have reported that prolong-
ation of renal graft survival resulted, when recipient mongrel dogs had been 
pretreated with multiple transfusions from a pool of non-related blood 
donors in combination with immunosuppressive treatment. 
We may conclude that attempts to achieve prolongation of graft survival 
by blood pretreatment in dogs were rarely succesful and not very well docu-
mented. Renal graft prolongation was successful when third party blood was 
combined with postoperative immunosuppression. Definite active enhance-
ment as can easily be achieved in other species has only been reported in a 
few cases, in which soluble antigens were used in combination with immuno-
suppressive treatment. Further experiments must be carried out in out bred 
animal models to study the effect of blood transfusions on kidney graft sur-
vival in man. 
3.4. Blood transfusions and prolongation of renal allograft survival in rhe-
sus monkeys 
Recently observations on renal allograft prolongation after blood transfu-
sions in rhesus monkeys have been reported by van Es et a!. (31 ). The renal 
allograft survival in SD and LD typed rhesus monkeys was studied after five 
transfusions of 20 ml fresh blood from third party blood donors were given 
in biweekly intervals. Donor and recipient were matched for two or three anti-
gens of the RhLA-A or-B locus. Grafting was performed II to 23 days after the 
last transfusion. A low dosage of immunosuppressive treatment was given. 
The mean survival time of the transfused monkeys was significantly longer 
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(MST = 48,9 ± 25,3 days) than the mean survival time ofnontransfused an-
imals with (MST: 11,0 ± 1,4 days) or without immunosuppression (MST: 
11,4 ± 3,5 days). The shortest interval between last transfusion and trans-
plantation correlated with the longest graft survival. The degree of histocomp-
atibility between blood donors and kidney donors did not show a correlat-
ion with graft survival. Lymphocytotoxins were produced in all transfused 
animals but no clear influence of antibody production was observed. Two re-
cipients showed positive crossmatch test prior to transplantation, without a 
hyperacute or accelerated rejection. Their prolonged graft survival can possibly 
be a result of antibodies against Ia orB cell antigens. VanEs eta!. (31) 
provide us with an excellent preclinical model to study the effect of blood 
transfusions on kidney transplant survival in man. They suggest that an non-
specific immunological mechanism is responsible for the graft protective act-
ion of pre transplant blood transfusions. 
3.5. Effect of blood pretreatment on renal allograft survival in DLA tissue 
typed beagle littermates (Introduction to the experiments) 
In the following five chapters our experiments with renal allograft transplant-
ation in beagle littermates after blood pretreatment will be reported. Some of 
the work has been published or has been submitted for publication. The beagles 
have been typed for the major histocompatibility complex (SD) antigens in all 
cases and by mixed lymphocyte defined (LD) antigens in some cases. 
Beagle dogs were chosen as experimental animals because of the experience 
with this well tested model in our laboratory. The short generation time and 
the litter size make the dog very well apt for histocompatibility research as has 
been shown in earlier communications (15, 139, 140, 142, 146). Data on graft 
survival have become available for skin, kidney, heart, liver, small bowel, pan-
creas, lung and bone marrow transplants in this model (II, 44, 45, 46, 67, 113, 
139, 141, 143, 144, 145). In all cases an influence of histocompatibility match-
ing has been observed (143). Attempts to prolong renal allograft survival by 
pretreatment with donor antigen have been unsuccessful thus far in our hands. 
Reports of prolonged graft survival by specific immunosuppression by donor 
antigens, without the use of aspecific immunosuppression, are rare in larger 
(outbred) experimental animals.However, we were tempted to test the effect of 
blood transfusions in our model without the use of immunosuppressive ther-
apy, since we considered the immunogeneic barrier between litterrnates low 
enough to obtain immunological enhancement. Azathioprine and prednisone 
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Summary 
A single transfusion of 200 ml of donor blood 14 days before renal transplant-
ation in prospectively DL-A tissue typed beagle littermates appeared to have 
an effect on graft survival. Seventeen per cent of the recipients did respond to· 
the transfusion with formation of lymphocytotoxic and haemagglutinating 
antibodies. These "responder dogs" rejected kidney grafts in an accelerated 
way compared with the "nonresponders" and with the non treated control 
dogs. Responsiveness appeared to occur in pairs of littermates, which suggests 
that responding potency is genetically determined. There was histological 
evidence of acute arteritis in the renal grafts of responders, whereas cell-
mediated rejection was noted in nonresponders. 
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Introduction 
Human kidney graft recipients will in most cases have received several blood 
transfusions before the time of transplantation, which often leads to formation 
of leukocyte antibodies (9, 16, I 7). Different effects of these transfusions on 
the survival of the grafts have been noted. Accelerated kidney allograft reject-
ion after blood transfusions has been described in patients with circulatory 
lymphocytotoxic antibodies which react with donor lymphocytes (12). On 
the other hand, it has been suggested in other publications (4, 15) that recip-
ients of renal grafts who had received many blood transfusions before kidney 
transplantation had a similar or even better course than patients that only re-
ceived a few transfusions. Recently Opelz eta!. (16) reported that an increas-
ed number of pre transplant blood transfusions leads to prolonged kidney 
graft survival. 
A beneficial effect of pretreatment with donor blood on allograft survival 
has been reported in different experimental animals. In rats, prolonged survi-
val of cardiac, renal, and skin grafts by pretreatment with whole blood has 
been described (6, 7, II, 13 ). In dogs a small dosage of blood injected s.c. had 
a specific immunosuppressive activity (8). In this species a major histocompat-
ibility complex has been described which resembles the human HL-A complex 
and which has been labeled DL-A (21). Storb eta!. (19) described a deleterious 
effect on graft survival of a single transfusion with donor blood before bone 
marrow transplantation in DL-A tissue typed dogs. 
The effect of one transfusion of donor blood on the survival of renal allo-
grafts in host-donor combinations with different DL-A relationships is the 
subject of this communication. 
Materials and methods 
Prospectively tissue typed beagles from an outbred colony were used. Tissue 
typing was done using a one-stage microcytotoxicity test, which has been 
reported previously (20, 21). The production and evaluation of test sera and 
the way DL-A specificities are recognized by these sera have been described 
elsewhere (22, 23 ). 
On the basis of the different segregation patterns of the typing sera in bea-
gle families, three experimental groups were formed: group I, two DL-A 
haplotype differences between donor and recipient; group 2, one DL-A haplo-
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type difference between donor and recipient; group 3, no DL-A haplotype 
difference between donor and recipient. 
Donor blood (200 ml) was collected in citrate and immediately transfused 
to the future recipient 14 days before kidney transplantation (day- 14). 
Lymphocytotoxic titers and haemagglutinating titers (19) were measured 
on days- 6 and - 1. Renal grafts were exchanged in pairs. The donor kidney 
was transplanted to the contralateral iliac fossa of the recipient following a 
standard procedure as described elsewhere (26). Contralateral nephrectomy 
was performed at the time of transplantation. 
Histological examination of the graft was done when the recipient died or 
when the serum creatinine levels rose above 1,000 f' moles/liter. In that case 
animals were killed by an overdose of Pentothal. All animals included in this 
series of experiments died exclusively from rejection. No immunosuppres-
sive therapy was ~ven. Survival data were analysed statistically with the Stu-
dent-Welch test (X stands for mean survival time). 
Results 
The survival times of the individual nonpretreated recipients of kidney allo-
grafts are given in Table 1 as reported by Westbroek et a!. (26). Statistical 
analysis showed a significant difference between the mean survival times of 
groups 1 and 3 (P < 0.001) and groups 2 and 3 (P < 0.005), but no signifi-
cant difference between groups 1 and 2 (0.10 > P < 0.20). 
The survival times of the individual recipients of kidney allografts after 
pretreatment with a single transfusion of donor blood (200 ml) 14 days 
before transplantation are given in Table 2. 







9, 9, 11, 11, 12, 12, 12, 14, 14,23,30,31 






a Survival times (days) for groups 1, 2 and 3 (see Materials and Methods for explanation of groups). 
b This graft was excluded from the statistical analysis. 
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Table~- Survival times of individual kidney allografts in littermate beagles after a transfusion with 
dnnor blooda. 
Group I Group 2 Group 3 
Day of Litterll Antibody Day of Litterb Antibody Day of Litte~ Antibody 
rejection at dayc rejection at dayc rejection at da:Yc 
-6 - 1 -6 -I -6 -I 
8 
'' + - 3 a' + + 8 a' + + 
10 b' - - 7 a' + + 12 
II b' - - II b' - 17 - -
12 c' - - II b' -
-
20 
13 a' - - II c - - 31 
18 d' 
-
- 12 d' - - 62 
19 c - - 18 d' - - > 300' 
20 f' - - 22 
' 
- - > 300d 
25 d' - - 43 f' - -
26 f' - - 68 f' - -
46 c' - -
x ~ 18.9 x ~ 20.6 x ~ (56.8) 
a Survival time (days) for groups I, 2 and 3 (see Materials and Methods). 









c Haemagglutination and microcytotoxicity tests were done 6 days and I day before transplantation. 








The slightly longer mean survival time of renal grafts in pretreated recip-
ients (18.9 days) compared to control dogs in group I (15.6 days) was not 
statistically significant. In groups 2 and 3, pretreated and control dogs also re-
jected in approximately the same period. In group 3 two out of the eight pre-
treated dogs survived longer than 3 50 days without any sign of rejection. 
It can be seen in Table 2 that only 5 out of the 29 dogs that received 
transplants in the three experimental groups had positive lymphocytotoxic 
and haemagglutination titers on days- 6 and-- I, varying from I : 32 to 
I : 256. They have been labeled "responders" (11, 14), whereas the other 
24 "nonresponders" did not develop antibody titers. 
The five responders showed accelerated graft rejection (3-12 days) when 
compared with the individual survival times of control dogs and pretreated 
dogs with negative titers. Nonresponder dogs did not reject their renal grafts 
before the 12th day. There was no clear correlation between sex or DL-A 
haplotype difference of donor and recipient and the number of responders. 
The responders of group 2 were littermates, which was also the case in 
group 3. It appeared that the individual pairs that exchanged grafts showed 
similar rejection patterns (Table 2). No significant difference between the 
mean survival time of nonresponders with transplants and control dogs could 
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be shown. The prolonged survival times of immunised nonresponders might 
reach significant levels in a larger material instead of the suggestive indication 
found in the present experiments. 
Histology. In the three experimental groups the difference in the histologi-
cal picture between the responders and the nonresponders was similar in 
that the responders showed early severe vasculitis with thrombosis and tissue 
destruction, whereas in the nonresponders the vasculitis was in all cases much 
less marked and the cellular infiltration more prominent. This difference be-
tween responders and nonresponders was most marked in group 3 (no haplo-
type difference). 
Discussion 
The effect of blood transfusion before kidney transplantation on the produc-
tion of lymphocytotoxic antibodies and the survival of the graft has been the 
subject of several recent investigations (16, 17). Except for a well known de-
leterious effect of blood transfusions, especially in the case of preformed an-
tibodies with antidonor activity, a beneficial effect has been described (17). 
In this study DL-A tissue typed beagle littermates were used. The effect 
of the prospective typing on the survival of small bowel, cardiac, pancreas, 
and kidney allografts has been described elsewhere (2, 3, 24-26). A signifi-
cant difference of survival times of identical and nonidentical kidney allo-
grafts has been previously reported (26). Two different rejection types were 
documented, depending on the DL-A haplotype difference. In identical com-
binations a cell-mediated rejection was obvious in post-mortem biopsies. In 
the nonidentical group, and especially in the group with a two-haplotype 
difference, a humoral rejection type with acute arteritis was predominantly 
present. 
After one blood transfusion with 200 ml of fresh donor blood 14 days 
before transplantation, 17% of the dogs produced lymphocytotoxic and 
haemagglutinating antibodies against their donors. In one of these five res-
ponder dogs positive antibody titers were only found on day- 6. No attempts 
were made to study the specificity of these antibodies. Four responder dogs 
consisted of two pairs. This finding, that responsiveness occured in two pairs 
of littermates and that comparable rejection patterns could be noted in many 
other pairs, would be compatible with speculations that responding potency 
is genetically determined. Obviously no conclusions can be reached yet on 
whether this presumed genetic control of responsiveness is achieved by one 
(II) or more mendelian systems (I). 
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Accelerated rejection occurred in the responder group, although hypera-
cute rejection was not seen. The nonresponders did not show any accelerated 
rejection. 
In the experimental group with a two-haplotype difference a prolonged sur-
vival time was noted compared with the non treated group, although the dif-
ferenc;" did not reach conventional significance levels. Prolonged survivals were 
also noted in two recipients that did not respond with antibody formation to 
blood transfusions of DL-A-identical donors. The possibility that these two 
identical donor-recipient pairs were in fact monozygotic twins cannot be ex-
cluded, inasmuch as both were of identical sex. The occurrence of monozy-
gotic twins in dogs has only been described once (5), however, and accor-
ding to our experience is highly infrequent. 
Histologically there were clear signs of severe vasculitis in all responders 
except one that survived for 3 days. The nonresponders did not show the ex-
pected humoral rejection type with vasculitis, but a predominantly cell-medi-
ated rejection was found instead. Thus, in the present experiments two ef-
fects of a pretransplant donor blood transfusion were noted. First, in a few 
dogs transfusions led to production of antibodies and a slightly accelerated 
rejection with histological evidence for an unusual severe vasculitis. Second, 
in the majority of the dogs antibody production did not occur, nor was 
there any deleterious effect of blood transfusion on graft survival, whereas 
the rejection pattern appeared to be of a cellular rather than of a humoral 
type. 
In the present study responders were identified by serological methods, 
which might be an unsatisfactory way to demonstrate such a complicated 
phenomenon. Moreover, these serological methods may lack adequate sen-
sitivity to demonstrate all types of antibodies, and it may well be that so-
called nonresponders do form specific antibodies, in which case the nor-
mal and prolonged survivals might be caused by enhancing antibodies. En-
hancement of renal allografts in dogs has been studied before with mode-
rate success (I 0). 
The fact that those dogs in the present experiments that responded to a 
blood transfusion with antibody formation also displayed a special histolo-
gical type of rejection, which was found to be caused by antibodies, does 
suggest that indeed these dogs were responders. 
It remains unclear whether unresponsiveness is genetically determined 
or specifically induced by donor-specific blood transfusions. Future expe-
riments will be aimed at the question of whether the unresponsiveness 
found in the present studies is genetically determined or not. The dog 
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will be an excellent model for such studies because of its short generation 
time and large litter size. If it again can be shown in further studies that 
under certain conditions blood transfusions can induce nonresponsiveness 
in the host, then the identification of these conditions becomes of prime 
importance to clinical allografting. 
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Summary 
Renal allografting was carried out between donor-recipient pairs of beagle lit-
termates that were mismatched for 2 DLA haplotypes. No immunosuppressi-
ve treatment was given. Two subcutaneous injections of whole blood from 
the prospective kidney donor 5 and I 0 days prior to transplantation resulted 
in accelerated rejection of the kidney graft when compared to graft survival 
in non-pretreated dogs and dogs that were pretreated with one intravenous 
transfusion of 200 ml donor blood 14 days before transplantation. A posi-
tive crossmatch correlated with accelerated graft rejection in most cases, 
although accelerated graft rejection was also observed in the presence of ne-
gative crossmatches. Results obtained by others in non-tissue typed dogs indi-
cating the induction of active enhancement of renal allografts by the sub-
cutaneous injection of donor blood could not be reproduced. 
The results stress the relevance of DLA tissue typing in testing tentative 
active enhancement protocols in this preclinical animal model. 
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Introduction 
Retrospective analyses have shown that blood transfusions prolong the survi-
val of a subsequent human kidney graft (1, 8, 10, 14, 15, 25, 26, 27, 28). 
This observation has been confirmed by prospective studies in larger experi-
mental animals. Third party blood transfusions combined with immuno-
suppressive treatment increased kidney graft survival in rhesus monkeys (5) 
and dogs (Obertop et a!., chapter 8). In rodents, enhanced graft survival 
can be obtained by giving organ donor blood without immunosuppressive 
drugs (6, 7, 19, 21, 22). Dogs have been used in the extrapolation of re-
sults obtained in rodents to men. Enhanced renal allograft survival by do-
nor blood pretreatment without the help of immunosuppression was des-
cribed by Halasz et a!. (II) in this species. At that time histocompatibility 
testing had not been developed yet in the dog. The aim of this investigation 
was to repeat the early experiments of Halasz et a!. (II) in tissue typed dogs. 
Failure to prolong graft survival in tissue typed dogs by subcutaneous injec-
tions of blood from the kidney donor suggests that the early results are pro-
bably due to chance host-donor histocompatibility and not to an enhancing 
or tolerazing effect of the injected donor blood. 
Materials and methods 
Prospectively DLA typed beagles from the colony of the Centraal Proefdie-
renbedrijf TNO, Austerlitz, The Netherlands (Dr. J. van Vliet) were used. 
Typing was performed in a one or two stage microlymphocytotoxicity test 
using sera and techniques previously described (32, 33,34 ). Donor and recip-
ient were littermates of the same sex and were 2 DLA haplotypes mismatch-
ed. In the experimental group (Group I) 2 ml of fresh whole blood from 
the prospective kidney donor was injected subcutaneously I 0 and 5 days 
prior to renal allografting, as reported by Halasz eta!. (II). No anticoagulant 
was used. 
Kidneys were exchanged between donor and recipient and transplanted in 
the left or right iliac fossa as previously described (35). A bilateral nephrec-
tomy was performed at the time of grafting. Recipients recieved no immuno-
suppressive treatment. Histological confirmation of rejection was obtain-
ed when animals died or were killed when the serum creatinine level rose 
above I ,000 1-' moles/liter. In this series, no dogs died from technical failu-
res. The mean survival time (MST) of kidney allografts in recipients inject-
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ed s.c. with donor blood was compared with the MST of kidney allografts 
in two other groups of dogs receiving a kidney from a 2 DLA haplotype 
mismatched sibling. One group (Group 2) received one intravenous transfus-
ion of 100 ml of donor blood 14 days before transplantation and one group 
(Group 3) received no blood before transplantation. The results of these two 
groups have been previously reported (24, 35). Crossmatches were performed 
in the one and two stage microlymphocytotoxicity test (29) and in the 
one stage test in Group 2. 
Results 
Renal allograft survival was not prolonged by two subcutaneous injections 
of 2 ml of donor blood. In contrast, the mean survival time of Group 1 (s.c. 
blood) was significantly shorter when compared with the MST of Group 2 
(i.v. blood) (p < .005) and the MST of Group 3 (no blood) (p < .005, Ta-
ble 1 ). The difference in MST between Group 2 and 3 is not significant 
(p >.l).ln three dogs in Group 1 (s.c. blood) and one dog in Group 2 
(i.v. blood) antibody production against the kidney donor was detected 
prior to transplantation. A positive crossmatch was found in some of the 
recipients that had decreased graft survival but not in all. Exclusion of dogs 
with antibodies did not change the relevance of the observations. No clear-
cut correlation between DLA inheritance and antibody production was 
seen. Two of the dogs with antibodies were litterrnates whereas the other 
two had litterrnates who did not produce antibodies. 
Discussion 
It has previously been shown that transfusions with whole blood do not 
protect a renal graft against rejection in dogs (2, 4, 24) and have a deleteri-
ous effect on bone marrow grafting in canine siblings (30). In rodents, how-
ever, prolonged kidney and heart survival can be obtained after pretreat-
ment with blood from the organ donor without immunosuppression (6, 7, 
19, 21, 22) although the effect differs according to the donor recipient com-
bination and depends on dosage and timing of the injections. Accelerated 
graft rejection has also been observed after donor blood injections in rats 
(22). Other protocols which were effective in prolonging allograft survival 
in rats, such as pretreatment with anti-donor sera (17) or administration of 
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anti-lymphocyte serum and donor bone marrow (23) were not effective 
in tissue typed dogs ( 16, 18). In other publications the succesful induct-
ion of active enhancement in dogs with (3, 12, 13, 36, 37) or without (11, 
38) immunosuppression has been reported. However, tissue typing was not 
employed and in view of the irreproducibility of some of these positive results 
the occurrence of chance donor recipient compatibility in the experimental 
groups alledgedly showing enhancement cannot be excluded. 
Table I. Survival of individual kidney allografts. 
Group I Group 2 
(2 ml donor blood day- 10 and- 5) (200 ml donor blood day- 14) 
day of litter* antibody day of litter* antibody 
rejection rejection 
3 ', 8 
' 
+ 
4 b' + 10 f, 
5 a' II f' 
6 c, 12 g' 
7 a' + 13 h' 
9 c' 18 h' 
10 d' 19 i 
10 d' 20 j ' 
II b' + 25 h' 
28 c' 26 j ' 
46 g' 
m.s.t. 9.3 m.s.t. 18.9 f--1---- p < .005"----_j L_ ____ p>.l** 
L. ------------ p < .005** 
* Littermates are denoted with similar letters. 


















The report of Halasz et al., ( 11) describing prolonged kidney graft survi-
val in dogs after subcutaneous donor blood injections is unique because of 
the use of the s.c. route of giving donor antigen and because it has been re-
ferred to as a clear example of active enhancement in the dog. Other invest-
igators have stressed that the route of injection is important in obtaining 
enhancement of an allograft (9, 13) and the most effective route is proba-
bly intravenous (31 ). Repeating the Halasz protocol in DLA tissue typed 
beagle littermates with a defined incompatibility between donor and recip-
ient did not lead to prolongation of kidney graft survival. Accelerated re-
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jection after s.c. donor blood injections was observed when compared with 
the non-pretreated or i.v. pretreated controls. This confirms that route of 
injection as well as dosage and timing of donor antigen pretreatment is of 
importance in altering kidney graft survival. In addition, these data show 
again that histocompatibility matching is an important variable in a pre-
clinical model as the dog and that two DLA haplotypes mismatched siblings 
can be used as a standard histocompatibility difference. The use of random 
donor recipient pairs with gross anatomical differences will not guarantee 
DLA differences (39). 
Hyperacute rejection (20) was not found in this series; all dogs produc-
ed urine immediately after transplantation. A positive crossmatch between 
recipient serum and donor lymphocytes predicted decreased graft survival 
in three out of four dogs, whereas accelerated rejections were seen in other 
cases despite negative crossmatches. This probably indicates a lack of sensiti-
vity of the crossmatch procedure as it is currently performed in the dog. 
In the present study we were again unable to demonstrate the applic-
ability of a so-called active enhancement protocol to the out bred tissue ty-
ped dog (2, 16, 18). The graft prolongation that can be obtained by third 
party blood transfusions combined with immunosuppression is probably 
not based on active enhancement (Obertop, eta!., chapter 8). A further 
exploration of the effect and mechanism of third party blood transfusions 
in a tissue typed dog model might be more rewarding and have a higher 
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Summary 
The relationships between immune reactivity after blood transfusions, 
subsequent kidney allograft survival and donor selection were studied 
in dogs. Animals with a high as well as a low serological immune reacti-
vity towards antigens contained in blood transfusion were observed. 
Genetic control of this reactivity or a linkage of this property to DLA 
sex or red cell markers inheritance was not apparent in the four beagles 
families studied. The two recipients with the lowest immune reacti-
vity scores were also found to be the longest survivors after a DLA mis-
matched kidney graft. Seven other recipients with higher scores rejec-
ted their DLA mismatched kidneys as rapidly as did untransfused ani-
mals. Kidney graft survival was decreased in some recipients of DLA 
identical kidneys (n = 5) presumably through sensitization for minor his-
tocompatibility antigens. A normal or an increased survival time of DLA 
identical kidneys was found in the remaining animals (n = 6). The majority 
of these recipients appeared to have a higher than average reactivity in two 
stage microcytotoxicicty testing. This might have been due to the presence 
of enhancing antibodies. Further studies in preclinical animal models are 
needed to define the optimal transfusion policy for human patients awai-
ting a kidney graft. 
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Introduction 
Several retrospective analyses of kidney transplantation in man have been 
made to determine the possible influence of prior blood transfusions on the 
survival of a kidney allograft and the efficacy of host/donor matching. The 
results indicated that (I) a positive cross match between kidney donor 
lymphocytes and a recipient's pregraft serum correlated positively with hy-
peracute rejection (15, 26); (2) conflicting observations were made concern-
ing a negative cross match. Several authors found a better graft survival in 
patients that had received blood transfusions prior to kidney grafting (10, 
13, 23, 24). Others reported that kidney graft recipients with lymphocyto-
toxic alloantibodies prior to grafting experienced a shorter average graft sur-
vival than recipients who did not produce antibodies following blood trans-
fusion (19, 24, 27, 28, 29, 32). This observation could not always be confirm-
ed in later studies (2, 3, 7, 8, 10, 16, 20). A beneficial effect of matching 
for HLA antigens (especially HLA-B antigens) on kidney graft survival was 
demonstrated in transfused patients with antibodies (12, 22, 29). This ob-
servation was also not always reproducible (3, 8). The variation in results 
obtained are a reflection of the difficulties inherent in an analysis of com-
plex clinical situations such as human kidney transplantation with many 
uncontrollable variables. A consequence of the conflicting results on there-
lationships between transfusions, kidney graft survival and donor selection is 
that a uniform "transfusion" policy cannot be established for human patients, 
who will require a kidney graft in the future. Too many blood transfusions 
might lead to a high degree of sensitization of the recipient, with a positive 
crossmatch to the majority of random unrelated kidney donors. However, 
too few blood transfusiOns might contribute to an overall decrease in aver-
age kidney graft survival, since patients who did receive blood transfusions 
prior to grafting appeared to experience a better survival than those patients 
who did not. 
A reliable preclinical animal model is evidently required to study this 
complex situation. Studies in inbred rats have shown that transfusion of do-
nor blood can result in prolongation as well as a shortening of kidney graft 
survival depending, among other things, on the rat strains used as donors and 
recipients (17). Attempts to extrapolate the conditions for successful rat 
blood and kidney transplants to outbred species of laboratory animals have 
so far failed. Studies in rhesus monkeys were recently reported; in this 
species prior blood transfusions did have a significant effect on kidney allo-
graft survival (9 ). 
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The present report deals with an ongoing analysis of the stated problem 
in the dog. This animal model has the advantages of ready availability, simple 
identification and high frequency of littermate donors, identical for the Ma-
jor Histocompatibility Complex (MHC), and the accumulation of previous 
experience in kidney grafting in this model under various conditions (5, 14, 
21, 36, 37). 
The aims of the current study were: 
a. to describe the specific immune reactivity of dogs after multiple third 
party transfusions (i.e. not autologous and not from the kidney donor); 
b. to investigate the possibility of a straight forward genetic control of 
such specific allogenetic immune reactivity; 
c. to determine the possible effects of prior third party blood transfusions 
on the survival of MHC identical or mismatched kidney allografts in non-
immunosuppressed recipients. 
Material and methods 
Four beagle families (a total of 24 offspring) were purchased from the 
Central Institute for the Breeding of Laboratory Animals (TNO, Zeist, The 
Netherlands). All the animals and their parents (whenever available) were 
typed for the genetic markers indicated below and all received blood trans-
fusions. Only the offspnng were used as kidney recipients and/or donors. 
Seven mongrel dogs from four different families were used as blood donors. 
They were selected on the criteria: I) DLA-SD different from the beagles, 
in an attempt to avoid cross immunization with the kidney donor; and 2) 
DEA 1.1. and 1.2. negative, to prevent the occurrence of transfusion reac-
tions after multiple transfusions (31 ). 
Genetic markers 
The Dog Major Histocompatibility Complex (DLA) 
Serologically defined (SD) antigens were determined by employing a micro-
cytotoxicity test, in which more than 70 antisera recognizing the specifici-
ties I, 2, 3, 7, 8, 9, I 0 of the DLA-A series, 4, 5, 6, 13, Rl6 and R20 of the 
DLA-B series and II, 12, Rl5 of the DLA-C series (30, 33, 34) were used. 
Lymphocyte defined (LD) antigens determine the reactivity in mixed lym-
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phocyte cultures (MLC). So-called LD typing cells were not used in this 
study. In 3 of the 4 families one way mixed lymphocyte cultures using a 
technique described elsewhere (6, 11 ), were performed. 
Dog Erythrocyte Antigens (DEA) 
The antigens belonging to the systems I, 2, 3, 4, 5, 6, 7 and 8 were deter-
mined using methods and reagents previously described ( 4, 31 ). 
Canine Secretory A flo-antigens ( CSA) 
The A, X and Y antigens were determined through the kind cooperation of 
Dr. A. Zweibaum, using methods described earlier by this group (38). 
Blood transfusions 
Each beagle received a I 00 ml transfusion which represented a pool of 
citra ted blood from seven different donors on days I, 7 and 14. Serum 
samples were obtained on day 21 and prior to each transfusion. Samples 
were inactivated for 30 min at 56°C and stored at -20°C until testing. 
The humoral immune response of the transfused animals 
Cell suspensions of the following animals were used to screen the sera of the 
transfused animals for antibody activity in the one and two stage modifica-
tion of the microlymphocytotoxic assay ( 1 ). 
I. blood donors, 
II. family members (including the kidney donor), 
III. the leukocyte panel, a group of twenty unrelated dogs of various (for 
the majority, undefined) breeds. 
All of the currently known DLA groups are represented in the panel. All sera 
were tested undiluted: for cell suspensions of groups I and II, three serum dilu-
tions (I : 2, I . 4, and 1 : 8) were also included. Each serum was given a 
reactivity score. This score was obtained by considering alllymphocytotoxic 
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reactions as positive where more than 25% of the lymphocytes were stained. 
Each positive reaction was multiplied by the reciprocal of the serum dilution. 
All scores of positive reactions per serum were added, divided by the maximum 
obtainable score and multiplied by a hundred. When undiluted sera were test-
ed, the strength of the reaction was scored as 4, 6 or 8 depending on the per 
centage of cells killed (25-50, 50-75, and 75-100 respectively). Here the anti-
body score was obtained by multiplying the positive reactions by their 
strength factor, adding all of these multiplications for each serum and divid-
ing it by the maximum obtainable score, and multiplying it by I 00. This 
scoring system was chosen to facilitate comparisons in immune reactivity 
among different animals in this and future experiments. 
Renal allograft 
The transplant was performed between days 21 and 30 of the protocol fol-
lowing a previously described standard procedure (36), which includes a 
bilateral nephrectomy of the recipient on the day of allografting. Donor 
kidneys came from littermate donors that were DLA identical (n = 14), 2 
DLA haplotype different (n = 8) or I DLA haplotype (n = 2) different. 
Postoperative treatment 
Antibodies and parenteral fluids were given during the first five post oper-
ative days following a standard, previously reported protocol (36). Immuno-
suppressive treatment was not given. Recipients were observed until 200 
days after grafting, until they died or were killed when serum creatinine 
levels rose above 1,000 11 mol/!. An autopsy was routinely performed and 
fresh specimens of the of the kidney graft were obtained for histopathological 
studies. 
Results 
The immune reactivity of the transplanted dogs 
The results obtained are summarized per immunized family in reactivity 
scores in Tables I and 2. 
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Table L Reactivity scoreal or sera from transfused dogs 
Family Dog 
•'' 
Sire 0 976 • 
Qdl 
Dame 886 • 
0 










Sire 02277 • 
0 
Dame 814 • 
0 













a see methods for computations 
b day as related to first transfusion 
c • =not done 
microlymphocytotoxicity 
one stage 
7 14 21 0 
• 0 • • 
• • • • 
50 92 85 0 
0 0 • • 
0 0 0 0 
:J 0 4 0 
2 7 3 0 
0 41 65 0 
16 17 10 0 
78 38 64 0 
0 0 4 0 
14 3 4 0 
l 3 0 0 
18 8 0 0 
8 20 19 0 
0 0 • • 
• 0 5 0 
• • • • 
l l 24 0 
53 31 39 0 
0 2 8 0 
0 25 65 0 
0 0 7 0 
5 29 38 0 
0 0 21 0 
15 43 59 0 
0 2 5 0 
0 19 46 0 
0 0 l 0 
0 0 3 0 
0 2 19 0 




































































d upper row gives scorer with cells of transfusion donors, lower row gives scores with cells of leukocyte 
panel. 
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a see methods for computation 
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d upper row gives scores with cells of transfusion donors, lower row gives scores with cells of leukocyte 
panel. 
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Before transfusion no antibodies were found. After transfusion anti-
bodies were found in all dogs. No prozones were noted in the titrations. 
Reactivity scores were generally higher in two-stage tests than in one-
stage tests. This is in accordance with the observed higher sentitivity of 
the two-stage test (I). However, the results obtained with the cells of the 
leukocyte panel indicated that different specificities are sometimes deter-
mined by the two methods. An example of both (i.e. difference in sensi-
tivity as well as specificity) is given in Figure I. In sera taken early in the 
immunization period, suggestive evidence for DLA specificity was found 
in the reactivity patterns observed against cells of the leukocyte panel using 
both serological techniques. The specificities found corresponded with 
those present on the cells of the transfusion donors. Family studies to con-
firm the DLA specificity of the produced reagents were not performed. Sera 
taken late in the immunization period, showed high frequencies of positive 
Figure 1. Reactivity of dogs after blood transfusions to cells of leukocyte panel in one (I) and two 
(II) stage microcytotoxicity _ 










serum D. 4.387 serum D. 4.338 
14 21 14 
Positive results indicated as bars of large black dots; weakly positive results as small black dots. The 
other results were negative. 
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results. A meaningful specificity analysis is not possible without the use of 
extensive absorptions. Such investigations were not performed in this study. 
In one-stage tests the reactivity of the sera is more pronounced against 
the cells of the leukocyte panel than against those of the blood transfusion 
donors. No such difference is found in two-stage tests, except just before 
the second transfusion. Reactivity scores of below 10 against the transfusion 
donors and below 20 against the leukocyte panel for all sera per animal were 
arbitrarily taken as cut-off points, to indicate low responders. If a higher 
reactivity score was found, an animal was designated as high responder. More 
high responders were found in the two-stage test. For each method for res-
ponsiveness determination a separate analysis of the genetic data and the 
kidney graft survival was made. 
Genetic control of immune reactivity after blood transfusions 
In the limited material studied, the segregation of high or low responsiveness 
to allogenetic blood tranfusions was compared to the segregation patterns of 
the markers listed in the Method section, including sex. An example of such 
a family study is given in table 3. Neither one-nor two-stage responsiveness 
appeared to be correlated with DLA, sex or DEA I, 4, or 5 inheritance. The 
segregation patterns for other DEA groups and CSA were not informative 
in the families studied. 
Table 3,Dog family study of immune reactivity after blood transfusions and different genetic markers 
immune reactivity 
DLA 
dogs haplotypes I stage II stage sex DEA CSA 
parents 0 AB not tested not tested 0 not tested 
9 CD high high 9 not tested 
offspring I AC low low 0 4,5,6,7 AY 
2 BC high high 0 1.1,4,5,6, 7 AY 
3 AC high high 9 1.1,4, 6.7 AY 
4 BC low high 9 1.1.4,5,6.7 AY 
5 AC low high 9 1.1 ,4, 6,7 AY 
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Immune responsiveness after blood transfusion, donor selection and kid-
ney graft survival 
The relationship between immune reactivity scores and graft survival times 
are given in Fig. 2. Four animals are not included in this table because of 
(a) technical failure of the kidney graft (2x), (b) a positive cross match be-
tween donor and recipient, resulting in accelerated rejection (one animal that 
rejected the kidney within 5 days) and (c) a DLA recombination which oc-
curred in one of the families (one animal that received along surviving, LD 
identical, SD mismatched graft; this will be reported in detail with results 
of other DLA recombinants in the future). 
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The results in Fig. 2 for the mismatched in one- and two-stage testing in-
dicate that the same survival was found in recipients with widely different 
reactivity scores. In both tests two animals with the lowest scores are the 
longest survivors (35 and 16 days). The recipients of DLA matched kidneys 
seem to show a longer survival with higher reactivity scores in two-stage 
testing. This observation has a statistical significance level of just below 
p = 0.05 (see table 4 ). A comparison with survival times of untransfused 
animals is given in Fig. 3 The results in the DLA mismatched animals are 
not altered by transfusions. The survivals of DLA identical kidneys show 
approximately the same medium survival time. However, a much wider 
range in results can be observed in the transfused group. 
Figure 3. hnmune reactivity scores and kidney graft survival. 
>200 l J • •• 
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See method section for computation of reactivity scores. 
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Table 4.Immune reactivity scores in two-stage testing and DLA identical kidney graft survival 
Reactivity score in II stage testing 
>50 <50 
survival ;;. medium 
survival time 4 2 6 
(33 days) 
survival <medium 
survival time 0 5 5 
4 7 II 
p ~ 0.045 
(Fisher exact test) 
Discussion 
The results obtained indicate that nonresponders against multiple allogeneic 
blood transfusions were not found. By an artificially chosen division point, 
animals could be divided into low and high responders. The percentage of 
high responders seems to be elevated in beagle dogs, in comparison to the 
results obtained in human patients, awaiting a kidney allograft. This differ-
ence might be due to a lower immune reactivity in the human patients with 
end stage renal failure than in the healthy dogs. Another possibility is the 
use of multiple (7) donors in one transfusion and the twice repeated admin-
istration of blood products from the same donors. This immunization 
scheme was chosen to ensure that each recipient of blood transfusion re-
ceived the same antigenic mixture in the same sequence. Perhaps higher 
reactivity scores were obtained by the application of this unusual 
transfusion regimen. This possibility will be subjected to further study. 
A search for a possible genetic control of immune reactivity after 
allogeneic blood transfusions is a gigantic task. A multitude of antigens is 
transfused in different dosages and a multitude of assays can be applied 
to screen the recipient's immune system for reactivity. Consistent simple 
genetic patterns of inheritance have been obtained in studies of the im-
mune response in which a low-limiting-dose of a simple antigen was used 
for immunization and one type of antibody was used to measure reactivity 
(18). The majority of such investigations showed that the genetic control 
of the immune response to such antigens was limited to the chromosomal 
region coding for the MHC (for dogs, see ref. 34 ). If one chooses to neg-
lect the existence of all of the extra complicating variables in blood trans-
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fusions and kidney grafting in comparison to the experiments with "sim-
plified" antigen-antibody responses, one might be tempted to expect a 
similar simple genetic control of immune reactivity towards all allogeneic 
tissues. In such a model a high or a low immune reactivity after blood 
transfusions would be predictive for a subsequent short or long kidney 
allograft survival. Such a working hypothesis can be rejected on the basis 
of the data obtained in the present study. The segregation patterns found 
in the dog families for high and low immune reactivity after blood trans-
fusions did not correlate with the inheritance patterns of any of the other 
markers investigated (DLA, sex, DEA I, 4 or 5). This excludes a simple 
relationship between any of these markers and an "allogeneic response 
locus". 
Similar results were previously obtained in studies of blood transfusions 
given after a kidney allograft. Antibodies were found in most of the long 
and in some of the short term surviving kidney graft recipients (5 ). A 
positive crossmatch between donor lymphocytes and recipient serum was 
found once in this series of experiments and was again as in previous human 
{15,25) and dog (21) experiences correlated with an extremely short graft 
survival. The kidney graft data for animals with a negative crossmatch, as 
listed in table 4, provide suggestive evidence for a variable significance of 
the intensity Of immune reactivity after blood transfusion. A very low 
reactivity might be beneficial to survival in the case of a DLA mismatched 
kidney; however, the number of animals with such scores is too low for a 
reliable analysis. High reactivity in two-stage testing appears to be more fre-
quent in recipients of longer surviving DLA identical kidneys (table 4). In 
two-stage microcytotoxicitv testing more and sometimes different (see 
fig. I) types of antibodies are found than in one-stage testing. Therefore 
high reactivity scores in two stage testing might be correlated to the pre-
sence of enhancing antibodies, only detectable in the two~tage and not in 
the one stage technique. 
A wider range of results around the medium DLA identical kidney graft 
survival time has been found in the present study, when compared to the 
survival times of similarly transplanted but untransfused beagles (36). 
This indicates the presence of two opposing tendencies; one towards pro-
longed, one towards shortened kidney graft survival in the transfused dogs. 
The tendency to a shorter survival of DLA identical grafts might be explain-
ed by the sentitization of the recipient prior to kidney grafting against 
minor histocompatibility antigens. Evidence has been obtained suggesting 
that some of these antigens are controlled by the sex chromosomes (35). 
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The tendency of a longer survival of DLA identical grafts might be caused 
by the induction of enhancing antibodies. The assumption of this balance 
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Summary 
Renal allografting was performed between DLA identical beagle littermates 
without immunosuppressive treatment. One transfusion of 200 ml of parent-
al blood was given 14 days prior to transplantation. A parent of the kidney 
donor and recipient was chosen as blood donor to induce the formation of 
antibodies against non DLA antigens that might enhance renal graft survival. 
Kidney graft survival times of transfused dogs were compared with the sur-
vival times of DLA identical non-transfused littermated. Blood transfusions 
did not have a significant influence on the median graft survival time. 
Antibodies against the kidney donor lymphocytes were not demonstrated 
after blood transfusions. However, antibodies were induced in three out of 
the six animals tested as shown by the reactivity of the sera of these animals 
against a lymphocyte panel. Antibodies occurred in animals with long as 
well as short surviving grafts. 
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Introduction 
Blood transfusions were reported to have a beneficial effect on the outcome 
of renal transplants in some human patients (I 0, 12, 19). However, blood 
transfusions will lead to antibody formation in a considerable number of 
patients increasing the chances of a positive crossmatch between recipient's 
serum and donor lymphocytes. This is a contraindication to transplanta-
tion because of the high risk of the occurrence of hyperacute rejection of the 
graft (14). Even when lymphocytotoxic antibodies induced by blood trans-
fusions are not directed against the kidney donor antigens, the outcome of 
the graft can be poor (II, 18, 20, 21 ), although this observation could not 
be confirmed in some studies (3, 5, 6). However, at least some patients 
will be lost for transplantation after sensitization by blood transfusions 
and a recent quantitative analysis of the consequences of deliberately trans-
fusing blood for kidney transplantation showed that at best this would lead 
to a marginal increase in average kidney graft survival time (2). Kidney 
transplantation in preclinical animal models is necessary to elucidate the 
mechanism and possible benefits of the effects of blood transfusions on 
renal allograft survival. Recently such a model was described in rhesus 
monkeys (9). In this species a detailled knowledge of genetic determinants 
of the major histocompatibility complex (MHC) has been obtained (I). 
The limited availability of unrelated and in particular related rhesus monkeys 
for kidney graft experiments led us to the development of a dog model where 
these limitations do not prevail. The dog major histocompatibility complex 
has been extensively analyzed in the past (26). Gene products of various loci 
within and close to the MHC can be recognized (LD, SD, Ir, PGM3). However, 
so-called Ia antigens which might be of relevance to graft prolongation (7) 
have not been identified yet in this species. In a dog model, efforts to·prolong 
renal graft survival by kidney donor blood pretreatment, have been unsuccess-
ful thus far (17). Antibodies were formed in 17% of the cases and led to accel-
erated, though not hyperacute, graft rejection. Multiple transfusions with 
pooled blood from non related mongrel dog donors gave rise to antibody 
production in all cases. A clear-cut predictable effect on graft survival was 
not noted. Suggestive evidence for deleterious as well as protective effects 
of prior blood transfusions on the kidney graft were found (Bullet al., 
Chapter 6). The aim of the present investigation was to find a method to 
separate deleterious effects of blood transfusions from protective effects 
by a judicious selection of blood and kidney donor. The working hypo-
thesis was that in the dog antibodies with enhancing properties are directed 
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against non-DLA antigens, i.e., antigens whose genetic control is on 
chromosomes distinct from the one carrying the dog MHC DLA. 
Evidence for enhancing properties of such antibodies has been obtained 
in rodents (7, 13). Graft destructive antibodies would be reactive with 
antigens of MHC loci. This hypothesis led to the selection of a blood 
donor that would stimulate antibody formation against DLA as well as 
against non DLA antigens in the hope that a better antibody induction against 
minor histocompatibility antigens would occur when a major histo-incompat-
ibility was concurrently present. A DLAidentical sibling was chosen as kidney 
donor antigens. The results obtained thus far have failed to fulfill the aim of 
the investigation. The conditions required for a predictable beneficial ef-
fect of pre-transplant blood transfusions remain to be defined. 
Materials and methods 
Dogs, histocompatibility testing, kidney graft procedure 
Prospectively tissue typed beagles of the Centraal Proefdierenbedrijf TNO, 
Austerlitz, The Netherlands (Dr. J. van Vliet) were used. 
Histocompatibility testing was performed by serology as well as mixed 
lymphocyte reaction as previously reported ( 4, 23, 24, 25, 26). Identity 
for the LD antigens was defined as the complete absence of any stimula-
tion in the mixed lymphocyte reaction in the presence of a positive controL 
Kidney grafting and recipient nephrectomies were performed at the 
same operation. Operative procedure and postoperative care were describ-
ed elsewhere (27). 
Experimental design 
Six groups of three SD as well as LD identicallittermates of the same sex were 
selected. One dog out of each triplet was transfused with 200 ml of blood 
of a parent 14 days prior to renal allografting. One dog was used as a kidney 
donor for one transfused and one non-transfused DLA identicallittermate. 
When this was technically feasible, one kidney of the non-transfused dog 
was transplanted in the kidney donor. No immunosuppressive treatment 
was given. Histological confirmation of rejection was obtained when the 




Sera of transfused dogs were screened for antibody activity immediately 
before grafting in the one and two stage modification of the microlympho-
cytotoxicity test (23) against cell suspensions of blood donors, kidney do-
nors and a leukocyte panel of 18 unrelated mongrel dogs. The cell panel 
was selected to provide a representation of the currently defined DLA anti-
gens. An immune reactivity score against the cell panel was computed as 
described elsewhere (Bull, et a!., Chapter 6). Briefly it consists of expres-
sing the antibody reactivity of a serum as a percentage of the maximum pos-
sible antibody response 
Exclusions 
Two dogs died because of technical failures and were excluded from the ana-
lysis. 
Results 
Donor recipient pairs and their survival times are given in table 1. 
Table 1. Parental blood transfusions and subsequent kidney graft survival. 
Kidney donor (non~ 
Blood donor transfused)a 
p 
-o 






M t.f. 0 
P =Father of the three identical siblings 
M = Mother of the three identical siblings 
= See materials and methods 
t.f. = Technical failure 

















Transfused dogs have a shorter survival time as compared with non-trans-
fused dogs. The difference is not statistically significant in a Wilcoxon rank 
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sum test (.05 < p <.I). Positive cross match tests or hyperacute graft reject-
ions were not seen. In transfused as well as non-transfused dogs a wide range 
in survival times was observed similar to one found previously in DLA iden-
tical donor recipient pairs (27). In three out of five triplets the transfused dogs 
rejected the kidney earlier than the non transfused dogs. Two out of the three 
untransfused dogs did not reject their graft at all. In one triplet graft survival 
of transfused and non-transfused littermates showed little difference (49 
and 44 days respectively). In one other triplet the transfused dog did not 
reject his graft whereas the non transfused dog died 46 days after transplant-
ation. The results of the screening for lymphocytotoxic antibodies are shown 
in table 2. 
Table 2 Lymphocytotoxic antibodies in transfused recipients prior to grafting 
Survival time against panel against blood donor 
in days 1 stage 2 stage 1 stage 2 stage 
18 25 25 +++ 
27 0 0 
28 0 0 
49 6 22 + 
100 0 6 




I and 2 stage 
A transfusion with parental blood to the propective recipient of an SD and 
LD identicallittermate kidney graft did not prolong the median graft sur-
vival time of transfused over non-transfused dogs. It was evident even from 
this small number that no consistent effect of one parental blood transfu-
sion could be observed. In the past a similar observation was made when 
one blood transfusion of the kidney donor was given (17). The present 
study with parental blood was performed with the hope that the addition of 
DLA differences to non-DLA differences between blood donor and kidnev 
graft recipient might lead to a better production of anti-non-DLA anti-
bodies. Some rare antibodies against non-DLA antigens are reactive in micro-
lymphocytotoxicity tests (26). The well known difficulties in establish-
ing reliable serological techniques for minor histocompatibility antigens, 
leave the possibility open that non-DLA antibodies against kidney donor 
82 
antigens were produced, notwithstanding a negative cross match (15). 
If they were produced, no in vivo effect was demonstrated as evidenced 
by the absence of a change in the median survival times of the transplant-
ed kidney. The antibodies found by one and two stage lymphocytotoxicity 
tests, were apparently not indicative for the formation of enhancing anti-
bodies, since antibody production occurred in some of the long as well as 
the short surviving animals. 
The result contradicts the working hypothesis that the careful selection 
of the blood donor will allow a separation of the deleterious from the pro-
tective effect of blood transfusions. Similarly, in human patients no effects 
of blood transfusions were noted on graft survival, if the donor was related 
to the recipient (22). In dogs different experimental circumstances as another 
transfusion schedule or the use of immunosuppression in the kidney graft 
recipients can be tested to confirm this first impression. The prolonged graft 
survival in unimmunosuppressed recipients of DLA identical kidneys has been 
noted previously (17, 27). Attempts are being made to elucidate the me-
chanism. The occurrence of monozygotic twins has been excluded as a 
cause for this phenomenon in the past (26). From this and other experi-
ments it is clear that a predictable prolongation of renal allograft survival 
in dogs is hard to obtain (Bull et al., Chapter 6). Recent evidence 
was obtained in dog studies that in immunosuppressed recipients benefi-
cial effects of blood transfusions on kidney graft survival are more easily 
demonstrated and can be predicted prospectively (Obertop et al., Chap-
ter 8). More information is required on the interaction between minor and 
major histocompatibility, immunosuppression and blood transfusions be-
fore appropriate guidelines for a reliable induction of kidney graft protect-
ion by blood transfusions can be given. 
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Summary 
Significant prolongation of survival of non-related DLA mismatched renal 
allografts has been obtained in beagle recipients receiving three blood trans-
fusions from nonrelated donors prior to kidney transplantation and a low 
dosage of immunosuppression after transplantation. Non-transfused DLA 
identical or DLA I haplotype different littermates of the transfused dogs 
were used as controls. Lymphocytotoxic antibodies were formed after the 
blood transfusions. A quantitative immune reactivity score correlated with 
graft survival. Low scores prior to transplantation were found in five transfused 
dogs that did not reject their allografts. High scores prior to transplantation 
were found in four animals rejecting their graft and in one dog that survived 
after an abortive rejection episode. The great similarities between the results 
obtained in this animal model and the observations made in human trans-
plant patients indicate that this model can be utilized for a further analysis 
of the possibilities of blood transfusions in protecting subsequent renal allo-
grafts from immunological rejection. 
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Introduction 
When blood transfusions are given to human patients with end stage renal 
failure, different effects can be observed on a subsequent cadaver 
kidney allograft, depending on the recipient's response to the blood transfus-
ion. 
If antibodies are produced directed against the kidney donor, as shown by a 
positive crossmatch between donor's lymphocytes and recipient's serum, a 
high frequency of hyperacute graft rejection can be expected (9, 15), 
If antibodies are produced, that are not directed against the kidney donor's 
lymphocytes but against third party lymphocytes, a shorter average sur-
vival time of the kidney graft is noted in comparison to patients without 
antibodies (7, 12, 13, 16, 17, 26). 
If no antibodies are detected after blood transfusions in future kidney graft 
recipients, a better allograft survival is observed in those patients as com-
pared to patients without preformed antibodies who did not receive blood 
transfusions (2, 8, 13, 14). 
The first two observations have led to a policy of withholding blood trans-
fusions from prospective kidney graft recipients to increase the chance of 
graft survival (I 0). However, in recent reviews figures for kidney graft sur-
vival were reported to show a downward trend (8, 20). This was at least, in 
part, attributed to the reluctance to transfuse potential kidney graft recip-
ients, whereby less patients would be transplanted in the category where 
blood transfusions had a beneficial effect on renal graft survival. 
In view of the high failure rate of human kidney grafts and the morbidity 
of clinical immunosuppression the development of clinically applicable 
methods which will lead to the prolongation of kidney graft survival is 
highly desirable. The inability to predict whether blood transfusions will 
lead to a beneficial or detrimental effect on subsequent kidney grafts indi-
cates the need for studies in an animal model resembling the human situa-
tion. In such a model the conditions might be worked out, in which the 
transfusions of blood before kidney transplantation have a consistent and 
predictable effect on graft survival. 
This report deals with a study on the effect of pre transplant blood trans-
fusions on renal allograft survival in tissue typed dogs. The results obtained 
show a great similarity to the human data and appear to be a good starting 
point for futher evaluation of the immunosuppressive quality of pretrans-
plant blood transfusions. 
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Materials and methods 
Kidney graft recipients 
Ten pairs of tissue typed beagle littermates of the Centraal Proefdierenbedrijf 
TNO, Austerlitz, The Netherlands, were used as recipients. Eight pairs were 
DLA-identicallittermates and 2 were I haplotype different, 4 pairs were 
males, 4 pairs were females and 2 pairs were of different sex. 
Kidney graft donors 
Ten male mongrel dogs of unspecified breeds were used as kidney graft do-
nors. 
Blood donors 
Seven non-related tissue typed mongrel dogs were used as blood donors. The 
donors were selected for negativity for DEA 1-1 and DEA 1-2 to avoid trans-
fusion reactions (19). 
Histocompatibility testing 
Histocompatibility testing was performed by serological methods as previ-
ously described (18, 21, 22). 
Blood transfttsions 
One dog of each pair received three I 00 ml blood transfusions with weekly 
intervals from three different blood donors out of the pool of seven dogs. 
The littermate did not receive blood transfusions and served as a control. 
Immune reactivity testing 
One and two stage microlymphocytotoxicity tests (I) were performed be-
fore each blood transfusion and before transplantation. Sera were tested 
92 
against lymphocytes of the kidney donor, blood donors and a panel of 18 
dogs of various - for the majority undefined -breeds. This panel was selec-
ted to present all the currently known DLA antigens (23). An immune re-
activity score against this panel was computed and expressed as the percen-
tage of the maximal obtainable score, including strength and titer of the 
reaction as weighing factors. 
Kidney transplantation 
Both kidneys from one mongrel donor were transplanted two weeks after the 
last blood transfusion in the left or right iliac fossa of a transfused and a 
non-transfused beagle littermate of a pair according to the technique describ-
ed before (24 ). Bilateral nephrectomy was performed at the time of trans-
plantation and one kidney of the non-transfused beagle was grafted in the 
mongrel kidney donor, when technically feasible. 
Immunosuppression 
Azathioprine (2 mg/kg body weight) and Prednisone (1 mg/kg body weight) 
was given daily per i.v. injection to all transplanted dogs postoperatively until 
they died because of graft rejection or until the 60th postoperative day when 
the experiment was terminated. 
Postoperative control 
Serum creatinine levels were estimated at least bi-weekly and histological 
confirmation of allograft rejection was obtained in all cases when dogs died 
before tje 60th postoperative day or when dogs were killed, when serum crea-
tinine levels rose above 1.000 l'mol/1. The Wilcoxon test was used for statisti-
cal evaluation of graft survival and immune reactivity data. 
Results 
Survival 
After three blood transfusions, nine out often renal allografts survived longer 
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than the comparable allografts from the same donor transplanted in non-
transfused dogs (table 1). One transfused animal and his non-transfused lit-
termate were both long survivors. Graft survival times of the transfused 
dogs showed statistically significant prolongation as compared with non-
transfused controls (P < 0,01) (figure 1). Mongrel dogs receiving kidneys 
from non-transfused beagles showed no difference in graft survival as 
compared with non-transfused beagles receiving mongrel kidneys (figure I). 
All dogs received the same immunosuppressive regimen. Random dog 
kidney grafts from DLA mismatched donors without immunosuppressive 
Figure 1. Renal allograft survival in transfused (TR) and non-transfused (NTR) beagle littermates 
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Table l DLA typing and renal allograft survival times. 
Mongrel blooddonors transfused :beagles non-transfused beagles mongrel kidney donor 
(recipient) 
nr DLA survival nr DLA survival nr survival 
typing days typing days days 
A.B.C I D651 0 6 2, 5,11/7,4,- lOP D6514 6 2, 5,11/7, 4,- 11 RH115 d 16 
D,E,F 6814 9 9, 4, 12/3,-,- 51 6817 9 9, 4, 12/3,-,- 48 RH116d 26 
G,A,B 6815 9 9, 4,12/9,4,12 49 6816 9 9, 4,12/9, 4, 12 29 RH117 6 
C,D,E I D 716 d 1, 13,-/2,5,11 63b D 717 6 1, 13,-/2, 5' 11 30 I RH118 d 16 
F,G,A D6711 d 2, 5, ll/3,-,Rl5 26 6715 9 2, 5, 11/3,-, Rl5 I RH119d 
B,C,D D6812 d 9, 4, 12/9,4,12 >60 D6813 d 9, 4, 12/3,-,- 16 RH120 d 15 
E,F,G D6710 d 9, 6, 12/7,-, ~ >60 D6714 d 9, 6, 12/7,-,- 20 RH121 d 12 
A,B,C 6516 9 9, 6, 12/7,4,- 21 D6511 d 9, 6,12/7, 4,- 15 I RH124 d 41 
B,E,F 6214 9 - 4,-/7,-,- >60 6215 9 - 4,-/7,-,- >60 I RH123 6 19 
G,A,B 6252 9 3, -;R15/2, 5, 11 >60 6253 9 9, 4,12/3,-,R15 19 I RH133 d 19 
a = graft rejection after discontinuation of immunosuppression 
\0 b =sepsis 
"' 
~ Table 2 Immune reactivity scores of transfused beagles before transfusions and transplantation and their relation to transplant survival. 
Immune reactivity scorea 
1st transfusion 2nd transfusion 3 rd transfusion transplantation 
Beagle 
1 stage 2 stage 1 stage 2 stage 1 stage 2 stage 1 stage 2 stage survival 
in days 
6214 3 3 4 37 I 12 I 5 >60 
6252 5 0 n.t. n.t. n.t. n.t. 5 7 >60 
D6812 n.t. n.t. 7 12 14 51 10 5 >60 
D6510 3 3 4 37 I 12 I 5 !Oib 
D 716 5 0 n.t. n.t. n.t. n.t. 5 7 63b 
D6710 3 7 43 51 32 60 18 40 >60c 
6814 3 4 4 8 5 12 II 40 51 
6815 3 5 17 47 II 51 II 36 49 
D6711 4 4 5 29 29 37 17 54 26 
6516 4 3 n.t. n.t. 20 28 n.t. n.t. 21 
n.t. =not tested 
= see materials and methods 
b ::=:: no rejection 
= abortive rejection episode 
treatment survive significantly shorter (figure I) (Bijnen, thesis, 1978). 
Seven beagles that survived more than 60 days after transplantation, were 
called long survivors (six transfused and one non-transfused). One dog died at 
day 63 because of sepsis and another dog died at day 101 because of graft 
rejection two weeks after discontinuation of the immunosuppression. In five 
dogs immunosuppressive treatment was gradually diminished over a four 
week period. One dog died of graft rejection two weeks after immunosup-
pression was discontinued, whereas no signs of graft rejection were recog-
nized in the other four dogs (three transfused and one non-transfused) more than 
four weeks after finishing immunosuppression. 
Rejection 
Four out of ten transfused dogs and only one out of ten non-transfused dogs 
did not show any significant elevation of serum creatinine levels 60 days after 
transplantation. In the other dogs three different rejection patterns could be 
distinguished by observing serum creatinine levels. 
Type 1: acute rejection 
Fast elevation of serum creatinine from normal to 1,000 ,umol/1 in about one 
week, beginning 1-2 weeks after transplantation. Two transfused beagles, five 
non-transfused and six mongrels showed this type of rejection (fig. 2a beagle 
6514). 
Type 2: chronic rejection 
Gradual rise of serum creatinine from normal to 1,000 ,umol/1 in two weeks, 
beginning 2-5 weeks after transplantation. Two transfused beagles, three 
non-transfused beagles and two mongrels showed this type of graft reject-
ion, as depicted in figure 2b for beagles 6815 and 6816. 
Type 3: abortive rejection episode 
One dog (D 6710) showed a transient rise of serum creatinine at the time 
his non-transfused control (D 6714) rejected his graft (fig. 2c). 
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Figure 2a. Posttransplant serum creatinine levels of a transfused beagle and DLA identical non-
transfused controL 
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Figure 2c. Posttransplant serum creatinine levels of a transfused beagle and DLA identical non-
transfused control. 
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Histology 
Histological signs of graft rejection were observed in rejected kidneys. Mono-
nuclear cellular infiltrates and vasculitis were found to some degree in 
all postmortem biopsies of the renal allografts rejected before day 60. Dif-
ferences in histological pictures were mainly quantitative. Mononuclear in-
filtrates were small and patchy in three out of four rejected kidneys of transfused 
recipients whereas extensive diffuse mononuclear infiltrates were present 
in all but one rejected kidneys of non-transfused beagles or mongrels. Vas-
culitis and ischaemic changes were present in all rejected kidneys. No clear 
correlation between type of clinical rejection and histology was seen. 
Immune reactivity 
Allogeneic immunization and pregnancy could be excluded in all beagles 
used in these studies and no antibodies were detected prior to blood trans-
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fusions. All beagles produced cytotoxic antibodies after blood transfusions. 
No antibodies were found against kidney donor lymphocytes (i.e. all cross-
match tests were negative). The immune reactivity score computed against 
a panel of 18 dogs was higher for the two stage modification of the lympho-
cytotoxicity test, which is in accordance with the higher sensitivity of the 
two stage test. Several patterns in the development of immune reactivity in 
time were observed. In some transfused beagles the peak of antibody produc-
tion was reached early in the course of blood transfusions (table 2 e.g. dogs 
D 6510 and 6812), whereas in others the peak was reached at a later stage 
and the immune reactivity score was still high immediately before transplan-
tation (table 2 e.g. dogs D 6711,6815, 6814). A high immune reactivity 
score before transplantation correlated with allograft rejection in four trans-
fused dogs and an abortive rejection episode in one, whereas low scores cor-
related with lack of rejection. The difference was statistically significant 
(P < 0.005). (table 3). 
Table 3. Immune reactivity scores of transfused beagles immediately before transplantation and their 







a = 14 days prior to transplantation 
b = abortive rejection episode 
graft rejection no graft rejection 
11,11,17,18b,20a I, I, 5, 5, 10 
5, 5, 5, 7, 7 
Score is significantly higher in recipients showing allograft rejection (p < 0.005 in Wilcoxon test for 
I· and 2 stage modification of lymphocytotoxicity test) 
Discussion 
Transfusions of non-related third party blood had a beneficial effect on 
canine renal allografts in this experiment, when recipients were treated post-
operatively with a low dosage of immunosuppressive drugs. The occurrence 
of chance histocompatibility in the transfused group was excluded by using 
DLA tissue typed sibling pairs as transfused and non-transfused recipients 
of kidneys from the same donors. Out of ten transfused dogs only four rejected 
their kidneys within 60 days; two in an "acute" and two in a "chronic" way. The 
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"acute" type of graft rejection was mainly seen in non-transfused beagle or 
mongrel kidney graft recipients. Two different types of graft rejection have 
been reported before in DLA tissue beagle littermates (24). 
The immunosuppresive regimen used led to a significant prolongation of allo-
graft survival by itself. The difference with other reports (5, 6, 25) in which 
a similar immunosuppresive protocol has been reported as ineffective, can be 
explained by the use of i.v. instead of i.m. or s.c. injections of the immuno-
suppressive drugs in this study. The suggestion in this study that immunosup-
pressive treatment is necessary to elicit the protective effect of pretransplant 
blood transfusions, is supported by previous experiments in tissue typed bea-
gle littermates in our laboratory. None or only minimal allograft protec-
tion could be achieved after blood transfusions if postoperative immunosup-
pression was not used. In other studies in non-tissue typed dogs, prolongation 
of allograft survival could also only be achieved when kidney donor an ligen pre-
treatment was combined with postoperative immunosuppression (5, 6, 25). 
Recently renal allograft protection by pretransplant blood transfusions was 
successful too in rhesus monkeys when immunosuppressive treatment was 
used postoperatively (3). However, the beneficial effect of the pre transplant 
blood transfusion scheme used in our present study has not yet been tested 
without immunosuppression. It is possible that earlier transfusion experi-
ments without addition of immunosuppression failed because the dose of 
transfused blood was too small, the same blood donor was used more than 
once, or the duration of the immunization scheme was too short (II). 
In transfused dogs a high immune reactivity score before transplantation cor-
related with graft rejection. No accelerated graft rejection has, however, been 
observed and even dogs that rejected their kidney did so later than their non-
transfused littermates. Low immune reactivity before transplantation occurred 
in transfused beagles that did not show any sign of graft rejection. If immune 
reactivity has a causal relationship to allograft rejection, it might be a useful 
parameter in the selection of the best moment for kidney transplantation in 
experimental animals or man. 
Low immune reactivity before transplantation would be useful and could be 
obtained by an increase of the interval between blood transfusions, the use 
of leukocyte poor or frozen blood (4) and the use of immunosuppressive 
treatment during blood transfusions. 
These speculations are in contrast with the findings of VanEs eta!., which 
suggest that a short interval between transfusion and grafting is optimal to 
obtain the best protective effect of pre transplant blood transfusion on kidney 
grafts in rhesus monkeys (3 ). 
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The mechanism of prolongation of kidney graft survival by third-party blood 
transfusions is unknown and further animal studies are required to elucidate 
the mechanism. It is evident that the immune reactivity is altered by blood 
transfusions. Graft destruction as well as protection might be induced in the 
recipient. The use of aspecific immunosuppression might lead to suppression 
of the destructive properties, while permitting full expression of the protect-
ive effect. What component in the blood induces the protective effect is 
unknown, although there is some evidence that erythrocyte transfusions will 
suffice to induce this effect ( 4 ). What the effector mechanism in the host is 
or whether a histocompatibility difference between blood donor and kidney 
recipient is required remains unknown. Enhancing antibodies are however 
unlikely to be induced by third-party blood transfusions since blood donors 
and kidney donors do not have all transplantation antigens in common that 
are necessary to induce specific enhancing antibodies. Our findings are in 
favour of a non-specific immunosuppressive effect being aroused by third 
party blood transfusions. This effect can be observed when cytotoxic anti-
bodies are low and immediate graft rejection is suppressed by immunosup-
pressive drugs. One of the possible mechanisms for this effect might be the 
induction of suppressor lymphocytes in the host. The data of this communi-
cation mirror the clinical observations. An excellent animal model is there-
fore available to study the mechanism of the protective effect of blood 
transfusions on renal allografts and to identify the most effective way to 
induce graft protection by blood transfusions. 
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General discussion and conclusions 
In the previous chapters of this thesis our studies on the influence of blood 
transfusions on renal allograft survival in DLA tissue typed beagles have 
been reported. The aim of these investigations has been threefold. 
First, development of a model in an out bred laboratory animal to study 
the relevance of blood transfusions in prospective kidney recipient on renal 
allograft survival. 
Second, study of possible correlation between pretransplant immune 
reactivity after blood transfusions and graft survival, searching for predictive 
criteria for graft survival in transfused future allograft recipients. 
Third, identication of the mechanism of the beneficial effect of blood 
transfusions on renal allograft survival. 
A beneficial effect of pretransplant blood transfusions on renal allograft 
prognosis in man has been reported since 1973 (4, 12a, 39, 42, 42a, 56, 57, 
71, 79, 87, 96, 97, 99, 102, 105). By 1966 a paradoxical effect after 
immunization had been observed since the expected deleterious effect 
of multiple pretransplant blood transfusions on the renal allograft was not 
seen (27, 60, 81, 85). However, the influence of pretransplant blood trans-
fusions on graft survival can be overshadowed by many other conditions in 
the clinical situation. HLA compatibility (5, 24, 38, 54, 55, 57, 58, 
82, 83, 92, 93, 98, 103, 107, 112, 114, 117, 118, 120, 121, 123), the 
presence of preformed cytotoxic antibodies (42a, 51, 54, 57, 89, 92, 93, 99, 
11, 117, 118, 121, 137) and the quality of postoperative patient care (1 00, 
104, 107) have their impact on graft survival. 
Although critically ill patients, older patients and hyperimmunized patients 
are accepted for renal grafting at this time, the gradual decline of one 
year renal allograft survival, with the slight increase in one year patient 
survival cannot be explained by these factors (56, 138). A decrease in 
the number of blood transfusions in prospective renal transplant recipients is 
probably responsible for deterioration in overall one year graft survival results. 
Sensitization by transfusions of whole blood has always thought to be dis-
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advantageous to prospective recipients since the presence of antibodies was 
correlated with accelerated or even hyperacute graft rejection (76). Because 
there is a correlation between duration of hemodialysis (73), number of 
blood transfusions, and cytotoxic antibody production (115), a reduced pre-
transplant hemodialysis period has been advised and transplantations are being 
carried out after only few or no previous blood transfusions. The protective 
effect of blood transfusions on human renal transplants has been pointed out 
by Opelz et a!. in several (most of them retrospective) studies (96, 97, 99, I 02, 
I 05). Yet some questions have to be answered before an universal blood trans-
fusion policy will be accepted by every transplantation physician or nephro-
logist ( 4 ). Experiments in laboratory animals are a proper way to test the 
effect of pretransplant blood transfusion in well controlled protocols. 
In small rodents, blood transfusions can prolong renal allograft survival 
indefinitely, in some donor recipient strain combinations (34, 35, 77). Donor 
blood has always been used as pretreatment in these studies and active immu-
nological enhancement is thought to be the mechanism (see ref. !36 for review). 
Reports on prolongation of renal allografts by donor antigen pretreatment 
without additional immunosuppressive therapy in dogs are scarce (75, 149). 
Only a few investigators report successful renal graft enhancement in dogs 
by pretreatment with subcellular donor antigen fragments in combination 
with suboptimal doses of immunosuppressive drugs (52, 53, 14 7, 148). 
Some data has recently become available on renal graft prolongation by 
third party blood pretreatment and post-operative immunosuppressive treat-
ment in rhesus monkeys (31) and prelimary data in mongrel dogs(!). As of yet, 
no studies on dogs have been published in which intravenous donor blood 
pretreatment without immunosuppression was succesful in prolongation of 
graft survival, but no histocompatibility matching was or could be performed. 
9.1. Blood transfusions and renal allograft survival in DLA tissue typed 
beagles 
Because of the availibility of beagle dogs in our laboratory and the exten-
sive experience by earlier transplantation and genetic studies in this animal 
(14, 15, 16, 44, 45, 46, 63, 65, 67, 139, 140, 141, 142, 143, 144, 145' 146) 
DLA tissue typed beagles have also been used in our experimental protocols. 
Litter size and shortness of generation time make the dog applicable for stu-
dies in which the effect of histocompatibility on allograft survival is tested 
(140). Well controlled series of renal allografting without the use of immune-
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suppressive treatment are possible in DLA tissue typed siblings. The effect 
of matching for loci of the major histocompatibility complex on renal allo-
graft survival has proved to be relevant in related and unrelated donor recip-
ient pairs. (140, 143, 144, 145, 146). Since matching for DLAin beagle 
littermates donor recipient combinations could be performed in our laboratory 
immunosuppression was thought to be superfluous in testing the effect of 
blood transfusions on graft survival. In one of our experiments we have attempt-
ed to achieve prolongation of renal graft survival by one transfusion (200 ml) of 
donor blood prior to grafting in DLA identical, DLA I and 2 haplotype dif-
ferent donor recipient combinations (chapter 4 ). A significant influence of 
histocompatibility matching was found as having been shown before in untreat-
ed beagle littermates (145). 17% of the dogs responded with antibody 
formation before transplantation and kidneys were rejected in an accelerated 
way by "responders" although no hyperacute rejection was seen. "Non-
responsiveness" after one blood transfusion correlated with a somewhat longer 
mean survival time in the non-identical groups as compared with non-trans-
fused controls, but no statistical significance could be determined. This negative 
result confirms the difficulty in obtaining active enhancement of renal graft 
without immunosuppressive therapy in dogs. 
Other experiments have been described that were initiated by the findings 
of Halasz et al. (48) in 1964. The authors found significant prolongation of 
renal allograft survival in dogs by two s.c. injections of donor blood prior 
to transplantation without further treatment. The results were somewhat in 
contradiction with other reports in which massive quantities of donor anti-
gens were used (49). The publication has been referred to as an example of 
active immunological enhancement in the dog. Halasz's protocol has been 
repeated by us in DLA 2 haplotype different beagle littermates. In the 
study of Halasz et al. (48) no tissue-typing was feasible and a chance histo-
compatibility matching in the pretreateclgroups was theoretically possible. 
In our study prolonga!ion of renal graft survival was not observed after s.c. 
blood injections. The grafts were rejected in an accelerated way and the mean 
graft survival time was shorter as compared with animals that had been pre-
treated with one i.v. donor blood transfusion and with non-pretreated con-
trols. (Chapter 5). Timing of transplantation, dosage of antigen and route of 
injection are probably important in the balance between accelerated rejec-
tion and graft enhancement, as has been previously stressed. (6). 
No protective effect (active enhancement?) on renal allografts could be 
obtained in our protocols by pretreatment with donor blood. Increase of 
the volume of the transfused donor blood was not feasible and multiple 
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donor blood injections would probably give rise to antibody production 
and a higber percentage of dogs rejecting their graft in an accelerated fashion, 
as described by others (23). 
Three third party blood transfusions were given in another study (Chapter 6) 
in which pooled blood of seven unrelated mongrel blood donors was used to 
transfuse four beagle families (Chapter 6). No effect of blood transfusions 
on renal allograft survival was obtained and the effect of immune reactivity, 
as measured by lymphocytotoxicity testing, on allograft survival after blood 
transfusion will be discussed in the next paragraph. No hyperacute rejection 
was seen althougb higb levels of cytotoxic antibodies were present in some 
graft recipients prior to transplantation. However, hyperacute rejection of 
renal allografts has not been observed by us in dogs, as has been reported in 
man (71) and rabbits (28). 
Furthermore, we have described an experiment in which we used one pa-
rental blood transfusion to pretreat the beagle recipient of a DLA identical 
littermate renal allograft in order to induce enhancing antibodies and to pre-
vent positive crossmatching. A DLA identical sibling was used as a non-trans-
fused control kidney recipient. (Chapter 7). The wide variation in graft survi-
val times of the DLA identical kidneys in transfused and non-transfused litter-
mates suggests both cytotoxic and enhancing effects of blood transfusions. 
But no correlation between blood transfusions and graft survival could be 
shown. Addition of postoperative immunosuppressive treatment may 
strengthen the weak effect of parental blood transfusions by inhibiting the 
rejection governed by minor histo-incompatibilities. This was however not 
tested. 
In our last set of experiments a low dosage of i.v. injected immuno-
suppressive drugs was given postoperatively. (Chapter 8). Results as report-
ed by others in so-called active enhancement studies in dogs (52, 53, 147, 
148) and blood transfusions experiments in rhesus monkeys (31) and dogs 
(I) seemed to suggest the importance of immunosuppression. Three third 
party blood transfusions (from different blood donors) were given to pro-
spective recipient dogs. Kidneys from mongrel dogs were grafted in trans-
fused beagles and non transfused DLA identical or DLA I haplotype dif-
ferent littermates in pairs. Significant prolongation of graft survival could be 
observed after blood transfusions and 50% of transfused renal allograft recip-
ients did not show any clinical sign of rejection. The aim of our studies as 
pointed out in the beginning of thi,. chapter, has thus been reached since a 
protocol for testing the effect of blood transfusions in the dog has been 
obtained and will be helpful in further experiments. 
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9.2. Antibody production and renal allograft survival 
The presence of preformed antibodies in the prospective human graft recip-
ient is regarded as a poor prognostic sign for the outcome of the graft. When 
antibodies are directed against the kidney donor's transplantation antigens, 
hyperacute rejection will occur in man in most cases. But even in the absence 
of a positive crossmatch between recipient's serum and donor's cells a delete-
rious effect on renal allograft has been described in many communications 
(7, 51, 89, 92, 93, 117, 118, 121 ). More recently however excellent outcome 
of renal grafts has been reported in the presence of preformed cytotoxic anti-
bodies (8, 9, 12a, 17, 36). Improvement of crossmatching by more sensi-
tive techniques will prevent renal allografting in a recipient that is presensi-
tezed against the kidney donor (17, 26). 
Antibodies are produced after pregnancies, former allotransplantations, 
and blood transfusions. Females have a higher percentage of preformed anti-
bodies although a one year graft survival seems not to be affected and HLA 
compatibility is less relevant in females than in males (7, I 03 ). Antibodies 
induced by a former kidney transplant seem to have a deleterious effect on 
second graft survival (51, 101 ). The duration of hemodialysis period cor-
relates with the number of blood transfusions (73) and antibody production 
(91) Fifty percent of the hemodialysis patients does not form antibodies at 
any time during hemodialysis, according to Opelz et al. (94, 96). Other in-
vestigators report a gradual increase of the percentage of sensitized patients 
after increase of the number of blood transfusions (I 15). Unresponsiveness 
after multiple small blood transfusions in human volunteers was only 20% 
and half of these non-responders had lost antibodies formed during the trans-
fusion period and were thus, secondary unresponsive (37). The loss of anti-
bodies during hemodialysis and after a previous renal transplant has also been 
reported by others (51, 94 ). Regardless of whether unresponsiveness of a pro-
spective kidney recipient is a genetically determined condition or has been in-
duced by blood transfusion, renal allograft survival is probably superior in 
non-responders (3, 42a, 86, 97, I 02, I 05), although it has been reported that 
transfused patients with cytotoxic antibodies have a better outcome of their 
graft than non-transfused patients (I 2a, 42a, 97, I 02, I 05). Presence of anti-
bodies after blood transfusions may always be deleterious for the patients. 
Many prospective recipients will be excluded from renal transplantation 
because of a positive crossmatch test (4, 42a) and patients with HLA lympho-
cytotoxins against a high percentage of a leukocyte panel may reject 
their graft in an accelerated way in spite of a negative crossmatch (89). Use 
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of leukocyte poor (21) and frozen blood (12a, 42, 42a) does not induce anti-
body production since leukocytes and probably platelets are the anti-
geneic substances in human blood. In a report by Fuller et al. the beneficial 
effect of frozen blood on human renal allografting in the absence of cytotoxic 
antibody production has been reported (42, 42a). Absence of cytotoxic 
antibodies after blood transfusions will thus be beneficial for the transplant 
candidate. 
Blood transfusions may also produce non cytotoxic antibodies or en-
hancing antibodies. Anti B-cell antibodies, that can be detected by B-cell 
crossmatch tests (32), may have an enhancing effect and may correlate with 
blocking factor activity in mixed lymphocyte reactions or other in vitro 
analogues of the cellular rejection reaction (13 ). Blocking factor activity 
has been reported in human sera of transfused patients and renal allograft 
recipients. A correlation between blocking factor activity in MLR and 
graft prognosis has been reported (116; 126, I 2 7, I 28 ), although these 
data are not confirmed by other studies in man and experimental animals 
(50, 72, I 06). 
Enhancing antisera can be produced by immunization by donor antigens 
in rodents (33, 41, 62). Active enhancement has been suggested to be the 
mechanism of prolonged kidney graft survival in rats after blood trans-
fusions (34, 35,77, 78), although passive transfer of serum oflong surviving 
transfused rats did not give graft protection in non-transfused rats (35). 
Enhancing or blocking antibodies has been reported once in dogs (63), 
but passive transfer of serum of long surviving recipient dogs was without 
effect on allograft survival (I). 
In our experiments in tissue typed beagles, (Chapter 4 and 5) the presence 
of positive crossmatches as detected by one and two stage modifications of 
the microlymphocytotoxicity tests led to accelerated graft rejection in most 
cases, although accelerated graft rejections were also seen when the cross-
matches were negative. After one donor blood transfusion, the percentage 
of responder dogs was low and no significant prolonged survival in non-res-
ponder dogs was seen (Chapter 4). Responsiveness seemed to be dependent 
on the number of blood transfusions, since dogs that received multiple 
transfusions of non-related donor blood produced cytotoxic antibodies and 
no non-responsiveness could be observed (Chapter 7 and 8). 
After subcutaneous injections of very small doses of donor blood in DLA 
non-identicallitterrnates, antibodies could be detected in 30% and accelerated 
graft rejection was the case in almost all s.c. injected animals regardless of the 
presence of antibodies (Chapter 5). The absence of antibodies in the other 
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70% may be explained by the used techniques, that are possibly too insens-
itive to detect all cytotoxic antibodies. 
The difference in graft survival between DLA non-identicallittermates 
treated with i.v. aad s.c. blood can be due to the difference in the route of 
injection, the dosage of antigen, and the number and timing of the injections 
(Chapters 4 and 5). Analysis of these factors seperately in DLA tissue 
typed beagles would be too laborious and it suffices to say that cytotoxic 
antibodies were formed both by s.c. as by i.v. pretreatment with donor 
blood without prolongation of renal allograft survival. 
A simple inheritance pattern of immune responsiveness was looked for 
in another study (Chapter 6). Four beagle families were transfused with 
pooled blood of non-related third party blood donors and segregation of 
high and low responsiveness was studied. No simple relationship between 
a hypothetical immune response locus and other genetic markers could be 
observed and there is little evidence of responsiveness being a genetically 
determined condition in the beagle dog. All dogs produced alloantibodies 
after three third party blood transfusions and graft survival was not greatly 
influenced by the degree of immune reactivity against a panel. The height 
of antibody production can be the result of an unusual transfusion 
schedule. Pooled blood had been used, and the same dogs were used as blood 
donors more than once in the same recipients (Chapter 6). 
In an attempt to stimulate enhancing antibody production without the 
chance of inducing a positive crossmatch test, beagle littermates were 
pretreated with one blood transfusion from one of the parents of the 
kidney donor and his DLA identical recipient, whereas a third DLA iden-
ticallittermate was used as a non-transfused control recipient (Chapter 7). 
No antibodies against the kidney donor were found in this protocol and 
antibodies against blood donor and a random lymphocyte panel correlated 
with a short allograft survival in one dog, whereas another dog with a low 
immune reactivity after one parental blood transfusion survived indefinitely 
as did two non-transfused animals. 
A strong predictive value of antibody production as expressed as immune 
reactivity,computed against a random lymphocyte panel, could be observed 
in our last study (Chapter 8) when three third party non-pooled 
blood transfusions prior to grafting were combined with immunosuppres-
sive therapy given postoperatively. All animals produced antibodies 
when tested against the panel and the level of immune reactivity was 
predictive for renal graft success. High immune reactivity correlated with 
graft rejection or an abortive rejection episode in one dog, but no 
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hyperacute or even accelerated rejection was observed and all transfused 
dogs survived as long or even longer than the non-transfused DLA tissue 
typed littermate controls. No graft rejection was seen when immune 
reactivity immediately before transplantation was low. The two stage 
lymphocytotoxicity test used for the estimation of immune reactivity is 
more sensitive than the one stage test. Our data confirms clinical obser-
vations that third party blood transfusions given prior to transplantation 
can give renal graft protection in the absence of cytotoxic antibodies. In 
the presence of antibodies no accelerated rejection is expected as long as 
crossmatching is negative. Immune reactivity only immediately before 
transplantation correlates with renal allograft prognosis in transfused dogs 
and the effect of the length of interval between last transfusion and trans-
plantation will be tested in future experiments. 
9 .3. Mechanism of the effect of pre transplant blood transfusions on renal 
allografts 
Three possible mechanisms will be discussed in the next paragraph. 
I. Blood transfusions lead to selection of prospective graft recipients on 
basis of responsiveness which is a genetically defined condition related 
to allograft rejection. 
2. Blood transfusions induce specific immunosuppression of the allograft 
rejection reaction. 
3. Blood transfusions induce aspecific immunosuppression of the allograft 
rejection reaction. 
9.3.1. Unresponsiveness as a genetically defined mechanism 
Unresponsiveness after multiple stimuli by blood transfusions with whole 
blood has been reported in man and the genetical determination of res-
ponsiveness has been suggested in man (57) as in mice (I 0). 
The increase in the number of blood transfusions results however in decrease 
of unresponsive patients (37, 115) and beagle dogs in our studies. And some 
of the so-called immune unresponsiveness may be secondary since transient 
elevations of antibody titers have been reported in man (37, 94, 96). The 
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presence or absence and quality of antibodies in man and experimental 
animals depends greatly on the sensivity of the techniques used (26). When 
responsiveness on non-related blood transfusions was studied in beagle fa-
milies segregation patterns of high and low responsiveness did not correlate 
with simple inheritance patterns and a relation of an immune response locus 
with other genetic markers seems unlikely at least in the dog. Our experi-
ments do not support the theory of a genetical determination of immune 
responsiveness in the dog. 
9.3.2. Blood transfusions induce specific immunosuppression 
Antibodies are formed by blood transfusion and are detected in lymphocyto-
toxicity tests. Leukocytes and platelets are responsible for antibody forma-
tion directed against products of the major histocompatibility complex. When 
cytotoxic antibodies are directed against transplantation antigens of the kidney 
donor, they can give rise to allograft rejection in cooperation with cellular me-
chanisms. Non-cytotoxic antibodies could have a protective effect on the renal 
allograft by moderating the rejection mechanism on a peripheral or central 
level. These antibodies could block the afferent limb of graft rejection reac-
tion by preventing initial graft recognition and no cytotoxic antibody produc-
tion will follow, or these non-cytotoxic antibodies combined with antigen 
in antigen antibody complexes could produce a central inhibition of immuno-
competent cells. Antibodies or antigen antibody complexes also could block 
the efferent limb of the graft rejection reaction, possibly by occupying the 
antigen receptor sites. A correlation between blocking activity in vitro and 
immunological enhancement has been reported in man (13). As a rule blocking 
antibodies are not detected by lymphocytotoxicity tests. Although a correla-
tion between cytotoxic and blocking antibody activity has been found (127, 
128), and sera of transfused patients or renal allograft recipients can show 
blocking factor activity in vitro models of cellular rejection like mixed lym· 
phocyte cultures (116, 127, 128). Blocking factor activity of sera of these 
patients correlates with excellent outcome of renal allografts in man. However, 
this correlation could not be confirmed by others in man as well as in experi-
mental animals (72, I 06). Blocking antibodies are possibly directed against 
HLA-D determinants and may be equal to B-cell antibodies that can possibly 
be detected in human recipients by a weak positive crossmatch (32) and ana-
logy with anti Ia antibodies in mice has been suggested (25, 61). Since cyto-
toxic and blocking antibodies will be induced by the same stimulus the ba-
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lance between graft protection and rejection will be delicate after blood 
transfusions. It is possible that blocking antibodies can on)y have their 
protective effect in the absence of cytotoxic antibodies as suggested for 
beagle dog recipients in our studies. Kidney graft survival after blood trans-
fusions in dogs, with low or absent immune reactivity, is longer as compared 
with non-transfused dogs, whereas both have no cytotoxic antibodies. The 
protective effect is not due to the mere absence of cytotoxic antibodies 
but a definite result of an induced specific protective mechanism. Presence 
of blocking antibodies has not been tested in our dogs yet and results of 
our experiments are not very much in favor of a specific immunosuppres-
sive action since a strong protective effect could be seen after only three 
transfusion of third party donor blood. Blocking or enhancing antibodies 
have to be directed against donor transplantation antigens and probably 
against HLA-D derived antigens. 
Therefore kidney donor blood will be necessary to elicit specific anti-
bodies because of the polymorphism of the HLA-D locus. Some clinical 
observations are in favor of an increased graft protection after an 
increasing number of transfusion (96) others are not (57). 
9. 3. 3. B load transfusions induce aspecific immunosuppression 
Three transfusions of non related blood gave a moderation of allograft re-
jection in 60% of the transfused beagle dogs in our experiments (Chapter 8). 
Transfusions of frozen blood without leukocytes in man gave as good graft 
protection as whole blood whereas practically no cytotoxic antibodies 
could be detected as reported by Fuller eta!. (42, 42a). It is attractive 
to speculate on the existence of an aspecific immunosuppressive mechanism 
independent of transplantation antigens. However no such aspecific immuno-
suppressive mechanism is evident, although the immunosuppressive activity of 
polysacharides as described by Caine et a!. (19) and the protective effect of 
leukocyte poor blood may be based on the same unknown mechanism. 
Stimulation of suppressor T cells derived from the spleen may be respon-
sible for inhibiting graft rejection in an aspecific immunosuppressive action 
(12,43). 
In conclusion, we can say that a significant prolongation of allograft sur-
vival in DLA tissue typed beagles was achieved after three third party blood 
transfusions prior to transplantation, when immunosuppressive treatment 
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was given post-operatively. Pooled third party blood transfusions did not 
protect renal allografts from rejection without additional immunosuppres-
sion, possibly because of the DLA lymphocytotoxins that were produced 
against a high percentage of a panel, probably by iterative transfusions of 
the same blood donors. 
Attempts to obtain active enhancement of renal allografts by i.v. and 
s.c. injections of blood of the prospective kidney donor or of one of the 
parents of the prospective kidney donor were unsuccesful, although no 
immunosuppressive treatment was given to those dogs. 
DLA antibodies detected after i.v. or s.c. injections of donor blood led 
to accelerated graft rejection, but no hyperacute graft rejection was observ-
ed. Accelerated graft rejection was also found after blood pretreatment in 
spite of a negative crossmatch. The technique used may be too insensitive 
to detect DLA antibodies in all cases. 
High and low immune reactivity against the leukocytes of a random dog 
panel was observed in the sera of beagle families that had been treated 
with pooled third party blood transfusions. Inheritance of "responsiveness" 
was studied and no simple inheritance pattern could be recognized. 
Immune reactivity prior to kidney transplantation had a highly significant 
value in the prediction of graft rejection in beagles that had received three 
third party blood transfusions before grafting and immunesuppressive treat-
ment after grafting. Low immune reactivity correlated with prolonged graft 
survival and high immune reactivity correlated with graft rejection. No 
support could be found in our experiments for unresponsiveness as a gene-
tically defined phenomenon. All dogs seemed to be able to respond with 
alloantibody production after blood transfusions and secondary unresponsi-
veness could be found since high immune reactivity after blood transfusions 
disappeared before transplantation. Active enhancement was probably not 
the mechanism responsible for graft protection in our experiments. It seems ·. 
unlikely, in the light of the polymorphism of DLA, that a strong graft pro-
tection could be obtained in 60% of the recipient dogs after only three third 
party (non-related) blood transfusions since in active enhancement anti-
bodies elicited by the transplantation antigens of the kidney donor play a role. 
Also in those experiments, in which active immunological enhancement was 
attempted by pretreatment with donor or parental blood, no prolongation of 
renal allograft survival was seen. Therefore, an aspecific protective mechan-
ism seems to be most likely, by which pre transplant blood transfusions can 
mitigate the graft rejection reaction. 
Blood transfusions are helpful in protection of the future allografts in 
I 15 
experimental animals as well as in man, but the induction of lymphocyto-
toxic antibodies remains a serious side-effect of blood transfusions since 
these antibodies may lead to hyperacute or accelerated graft rejection or at 
its least to exclusion or delay of renal allografting in transplant candidates 
because of positive crossmatch tests. 
Therefore, blood transfusions have to ideally be carried out without the 
chance of inducing cytotoxic antibodies. This may be achieved by the use 
of frozen-thawed blood, leukocyte poor blood, the use of immunosuppres-
sion during transfusion or increase of the interval between transfusions. 
When antibodies can still be detected after pretransplant blood transfusions, 
it seems advisable to perform kidney transplantation at the moment that the 
immunereactivity of the patient serum against a leukocyte panel is low or 
absent. 
Before a general blood transfusion policy can be designed more research 
in laboratory animals will be necessary. Because of its striking similarity to 
the human situation our experimental protocol in DLA tissue typed beagles 




In this thesis studies on the effect of pretransplant blood transfusions on 
renal allograft survival in the dog are reported. These studies were initiated 
by the fact t11at blood transfusions given to patients with end stage renal 
failure are reported to have a protective effect on the future ren~l allo-
graft. Deterioration of worldwide kidney transplant survival in recent years 
may be caused by the policy to avoid blood transfusions to prospective 
kidney graft recipients because of the chance of sensitization that may 
lead to hyperacute or accelerated graft rejection. 
After an introduction to this thesis in Chapter 1, the literature on the 
effect of blood transfusions on cytotoxic antibody production and renal 
allograft survival in mean is discussed in Chapter 2. 
Although many observations in human renal allograft recipients are 
in favor of the benificial effect of pretransplant blood transfusions on the 
kidney graft, many factors can obscure this effect and no parameters are 
available to predict the outcome of a renal allograft after blood transfusions. 
Transfusion and transplantation experiments are necessary to elucidate the 
mechanism of the protective effect of blood transfusions and to develop a 
transfusion policy in prospective human kidney recipients. 
In Chapter 3 a review is given of the literature on experiments in labora-
tory animals in which the effect of pretransplant blood transfusions on 
renal allograft survival was tested. The attention is focused on the reports 
of experiments in the dog. In this animal prolongation of renal allograft 
survival by prior blood transfusions is hard to obtain in contrast with the 
findings in similar experiments in small rodents. 
The essential part of this thesis is our own experimental work, reported 
in the Chapters 4, 5, 6, 7, and 8. Studies on the effect of pre transplant 
blood transfusions on renal allograft survival in DLA tissue typed beagles 
were performed in the Laboratory for Experimental Surgery of the Eras-
mus University, Rotterdam, the Netherlands. The five chapters are written 
in the form of scientific papers. Chapter 4 and 5 have been published in 
Transplantation. Chapters 6, 7 and 8 have been submitted for publication. 
In Chapter 4 (first experiment) the effect of donor blood pretreat-
ment on cytotoxic antibody production and renal allograft survival in 
DLA identical and non-identical beagle littermates is reported. Antibody 
production and accelerated graft rejection was found in 17% of the dogs. 
Non-responders did not show a significant prolongation of renal allograft 
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survival. Genetical determination of responsiveness is suggested in this 
chapter. 
In Chapter 5 (second experiment) the report of an experiment in 2 DLA 
haplotype different beagle littermates is given. Future renal allograft recip-
ients were pretreated with s.c. injections of donor blood. Accelerated 
graft rejection was found, which is in contrast with earlier findings by 
others, reporting active enhancement of canine renal allografts in a similar 
experimental protocol. The importance of tissue typing in these types of 
studies is stressed. 
In Chapter 6 (third experiment) transfusion and kidney transplantation 
experiments are described in beagle families. Dogs received transfusions 
of pooled non-related blood and low and high immune reactivity tested 
against a random dog leukocyte panel was recognized. No simple inheritance 
pattern of responsiveness was found. Renal allograft survival was not greatly 
affected by the pretransplant blood transfusions and immune reactivity cor-
related with the outcome of the graft only in some animals. 
The experiment reported in Chapter 7 (fourth experiment) deals with the 
effect of one pretransplant transfusion of parental blood on the survival of 
DLA identical sibling renal grafts. Parental blood was used to induce non-
DLA (enhancing?) antibodies. No accelerated graft rejection was seen neither 
was a definite prolongation of renal graft survival. 
In the experiment described in Chapter 8 (fifth experiment) immunosup-
pressive treatment was given postoperatively and third party blood was trans-
fused three times prior to grafting of a non-related, non-identical kidney in a 
beagle recipient. A non-transfused DLA identical or I haplotype different 
littermate served as control. Prolongation of allograft survival was highly 
significant and 50% of the transfused recipients did not show any sign of 
graft rejection. Immune reactivity prior to transplantation showed a highly 
significant correlation with kidney graft prognosis. 
In Chapter 9 the foregoing experiments are discussed and hypotheses for 
the mechanism of the protective action of pretransplant blood transfusions 
are given. It is concluded that pretransplant blood transfusions can protect 
canine renal allografts from immunological rejection. Blood transfusions have 
ideally to be carried out without the chance ofinducing cytotoxic antibodies. 
When antibodies can still be detected, after pretransplant blood transfusions, 
it seems advisable to perform kidney transplantation at the moment that the 
immune reactivity of the recipient is low. An excellent model has been ob-
tained in the dog to develop a blood transfusion policy, in order to prevent 
renal allografts from immunological rejection in man. 
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SAMENVATTING 
In dit proefschift worden experimenten beschreven, die betrekking hebben 
op het effect van bloedtransfusies op de niertransplantaat overleving bij de 
hond. De uitvoering van deze experimenten werd gestimuleerd door het 
feit dat bloedtransfusies gegeven aan patienten met een terminale nierin-
sufficientie een beschermend effect op het toekomstige niertransplantaat 
zouden hebben. Een achteruitgang van niertransplantaat overleving in de 
laatste jaren is wellicht te wijten aan het beleid om bij toekomstige nier-
transplantaat ontvangers geen bloedtransfusies te geven in verband met de 
1(ans op sensibilisatie, waarna hyperacute of versnelde transplantaat afsto-
tingen mogelijk zijn. 
In hoofdstuk I wordt een inleiding tot dit proefschrlft gegeven. Hierna 
volgt een overzicht van de literatuur betreffende het effect van bloed-
transfusies op de vorming van cytotoxische antistoffen en niertransplan-
taat over!eving in hoofdstuk 2. 
Hoewel een aantal studies wijzen op een gunstig effect van vooraf-
gaande bloedtransfusies op het niertransplantaat, kunnen vele factoren 
dit effect maskeren. Er zijn geen parameters, die het succes van een nier-
transplantatie na bloedtransfusies kunnen voorspellen. Transfusie en trans-
plantatie experimenten zijn noodzakelijk om het mechanisme van het 
beschermde effect van bloedtransfusies op te helderen en om een bloed-
transfusie beleid te ontwikkelen voor toekomstige ontvangers van een 
niertransplantaat. 
Hoofdstuk 3 bevat een sam en vatting van de publica ties van experimenten 
in proefdieren, waar het effect van voorafgaande bloedtransfusies op nier-
transplantaat overleving werd onderzocht. In het bijzonder wordt de aan-
dacht gevestigd op publicaties van niertransplantatie experiment en in de 
hond. In dit proefdier wordt verlenging van de transplantaat overleving 
na voorafgaande bloedtransfusies slechts met moeite verkregen, in tegen-
stelling tot soortgelijke experimenten in kleine knaagdieren. 
Het belangrijkste gedeelte van dit proefschrift word! gevormd door ons 
eigen experimentele werk, dat word! beschreven in de hoofdstukken 4, 5, 
6, 7 en 8. Het onderzoek naar het effect van bloedtransfusies voor trans-
plantatie op de overleving van niertransplantaten in getypeerde beagles 
werd verricht in het Laboratorium voor Experimente1e Chirurgie van de 
Erasmus Universiteit te Rotterdam. 
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De vijf hoofdstukken zijn geschreven als wetenschappelijke publica ties. 
Hoofdstuk 4 en 5 werden gepubliceerd in Transplantation. De hoofdstuk-
ken 6, 7 en 8 werden recent ter publikatie aangeboden. 
In hoofdstuk 4 (eerste experiment) wordt het effect van voorbehande-
ling met donorbloed beschreven, op niertransplantaties tussen DLA iden-
tieke en niet-identieke beagle "littermates". Productie van antistoffen en 
versnelde transplantaat afstoting waren het gevolg in I 7% van de honden. 
"Non-responders" vertoonde geen significant verlengde niertransplantaat 
overleving. Een genetische controle van responderschap wordt in dit hoofd-
stuk gesuggereerd. 
In hoofdstuk 5 (tweede experiment) wordt verslag gedaan van een expe-
riment in 2 DLA haplotypen verschillende beagle 'littermates". Toekomsti-
ge niertransplantaat ontvangers werden behandeld met subcutane injecties 
met donorbloed. Versnelde transplantaat afstoting was het gevolg, in tegen-
stelling tot vroegere observaties door anderen, die actieve enhancement van 
niertransplantaten in de hand vonden in een soortgelijk experimenteel pro-
tocol. Het belang van weefseltypering in dergelijke studies wordt benadrukt 
In hoofdstuk 6 (derde experiment) worden transfusie en transplantatie 
experimenten beschreven in beagle families. De honden ontvingen voor 
transplantatie transfusies uit een bloed "pool" van niet verwante bloeddo-
noren. Een ''hoge" en "!age" immuunresponse tegen een panel van honden-
leucocyten werd gevonden. Een eenvoudig systeem van overerving van het 
"responderschap" werd niet gevonden. De niertransplantaat overleving 
werd nauwelijks beihvloed door de bloedtransfusies voor transplantatie. De 
immuunresponse voor transplantatie correleerde met transplantaat overle-
ving in enkele honden. 
In het volgende experiment in hoofdstuk 7 (vierde experiment) wordt 
het effect beschreven van een transfusie met bloed van een van de ouders, 
voor transplantatie, op de overleving van een DLA-identiek verwant nier-
transplantaat. Ouderlijk bloed werd gebruikt om non-DLA antistoffen op 
te wekken, die enhancement zouden kunnen bewerkstelligen. Geen ver-
snelde afstoting werd gezien, evenmin een duidelijk verlengde transplantaat 
overleving. 
In het onderzoek dat wordt beschreven in hoofdstuk 8 (vijfde experi-
ment) werd immunosuppressive behandeling gegeven na transplantatie en 
drie maal werd onverwant bloed getransfundeerd voor transplantatie van 
een nietverwante, niet identieke nier. Een niet getransfundeerde DLA iden-
tieke of I haplotype verschillende 'littermate" diende als controle ontvan-
ger. Duidelijk significante verlenging van niertransplantaat overleving werd 
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gezien en 50% van de getransfundeerde beagles vertoonden geen enkel te-
ken van transplantaat afstoting. De immuunresponse voor transplantatie 
correleerde goed met de niertransplantaat overleving. 
In hoofdstuk 9 worden de voorafgaande experimenten besproken en hypo-
thesen voor het mechanisme van de beschermende werking van bloedtrans-
fusies op een niertransplantaat worden vermeld. 
Dit proefschrift word! besloten met de conclusie dat bloedtransfusies 
voor de transplantatie een beschermende werking hebben tegen de immu-
nologische afstotingsreactie van niertransplantaten bij de hond. De produc-
tie van cytotoxische antilichamen na bloedtransfusies dient voorkomen te 
worden en wanneer antilichamen loch aanwezig zijn verdient het aanbeve-
ling om de niertransplantatie te verrichten wanneer de immuunresponse van 
de ontvanger laag is. We hebben een bruikbaar diermodel verkregen dat 
voor verdere onderzoeken gebruikt kan worden, die er op gericht zullen 
zijn een bloedtransfusie beleid te ontwikkelen waardoor niertransplantaten 
tegen afstoting beschermd kunnen worden. 
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